

HANDBOOK OF
PHARMACEUTICAL
EXCIPIENTS

THIRD EDITION



APhA
American
Pharmaceutical
Association



Pharmaceutical Press

EDITED BY
ARTHUR H. KIBBE

**Handbook of
PHARMACEUTICAL
EXCIPIENTS**

Handbook of PHARMACEUTICAL EXCIPIENTS

Third Edition

Edited by

Arthur H. Kibbe, Ph.D.

Professor and Chair
Department of Pharmaceutical Sciences
Wilkes University School of Pharmacy
Wilkes-Barre, Pennsylvania



American Pharmaceutical Association
Washington, D.C.



London, United Kingdom

Published by the American Pharmaceutical Association
2215 Constitution Avenue NW, Washington, DC 20037-2985, USA
www.aphanet.org
and the Pharmaceutical Press
1 Lambeth High Street, London SE1 7JN, UK
www.pharmpress.com

© 1986, 1994, 2000 American Pharmaceutical Association and Pharmaceutical Press

First edition 1986
Second edition 1994
Third edition 2000

Printed in the United States of America

ISBN: 0-85369-381-1 (UK)
ISBN: 0-917330-96-X (USA)

Library of Congress Cataloging-in-Publication Data

Handbook of pharmaceutical excipients / edited by Arthur H. Kibbe.--3rd ed.
p. ; cm.

Includes bibliographical references and index.

ISBN 0-917330-96-X

I. Excipients--Handbooks, manuals, etc. I. Kibbe, Arthur H. II. American Pharmaceutical Association.

[DNLM: 1. Excipients--Handbooks. QV 735 H236 2000]

RS201.E87 H36 2000

615'.19--dc21

99-044554

A catalogue record for this book is available from the British Library.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without the prior written permission of the copyright holder. The publisher makes no representation, express or implied, with regard to the accuracy of the information contained in this book and cannot accept any legal responsibility or liability for any errors or omissions that may be made.

Managing Editor: Melanie Segala
Copyeditor: Paul Gottehrer
Indexer: Lillian Rodberg
Compositor: Roy Barnhill
Cover Designer: Tim Kaage

Contents

| | | | |
|--|-------|--|-----|
| <i>Committees</i> | vii | Cholesterol | 138 |
| <i>Contributors</i> | ix | Citric Acid Monohydrate | 140 |
| <i>Additions to the Third Edition</i> | xii | Colloidal Silicon Dioxide | 143 |
| <i>Related Substances</i> | xiii | Coloring Agents | 146 |
| <i>Preface</i> | xv | Corn Oil | 154 |
| <i>Acknowledgments</i> | xvii | Cottonseed Oil | 156 |
| <i>Notice to Readers</i> | xviii | Cresol | 158 |
| <i>Selected Bibliography</i> | xviii | Croscarmellose Sodium | 160 |
| <i>Abbreviations</i> | xix | Crospovidone | 163 |
| <i>Units of Measurement</i> | xx | Cyclodextrins | 165 |
| | | Dextrates | 169 |
| | | Dextrin | 172 |
| | | Dextrose | 175 |
| Monographs | | Dibutyl Sebacate | 178 |
| Acacia | 1 | Diethanolamine | 180 |
| Acesulfame Potassium | 3 | Diethyl Phthalate | 182 |
| Albumin | 5 | Difluoroethane (HFC) | 184 |
| Alcohol | 7 | Dimethyl Ether | 186 |
| Alginic Acid | 10 | Docosate Sodium | 188 |
| Aliphatic Polyesters | 13 | Edetic Acid | 191 |
| Alpha Tocopherol | 18 | Ethylcellulose | 195 |
| Ascorbic Acid | 21 | Ethyl Maltol | 201 |
| Ascorbyl Palmitate | 25 | Ethyl Oleate | 203 |
| Aspartame | 27 | Ethylparaben | 205 |
| Bentonite | 30 | Ethyl Vanillin | 208 |
| Benzalkonium Chloride | 33 | Fructose | 210 |
| Benzethonium Chloride | 36 | Fumaric Acid | 213 |
| Benzoic Acid | 38 | Gelatin | 215 |
| Benzyl Alcohol | 41 | Glucose, Liquid | 218 |
| Benzyl Benzoate | 44 | Glycerin | 220 |
| Bronopol | 46 | Glyceryl Monooleate | 223 |
| Butylated Hydroxyanisole | 49 | Glyceryl Monostearate | 225 |
| Butylated Hydroxytoluene | 51 | Glyceryl Palmitostearate | 228 |
| Butylparaben | 53 | Glycofurol | 230 |
| Calcium Carbonate | 56 | Guar Gum | 232 |
| Calcium Phosphate, Dibasic Anhydrous | 60 | Heptafluoropropane (HFC) | 234 |
| Calcium Phosphate, Dibasic Dihydrate | 63 | Hydrocarbons (HC) | 236 |
| Calcium Phosphate, Tribasic | 68 | Hydrochloric Acid | 238 |
| Calcium Stearate | 70 | Hydroxyethyl Cellulose | 240 |
| Calcium Sulfate | 73 | Hydroxypropyl Cellulose | 244 |
| Canola Oil | 77 | Hydroxypropyl Cellulose, Low-substituted | 249 |
| Carbomer | 79 | Hydroxypropyl Methylcellulose | 252 |
| Carbon Dioxide | 83 | Hydroxypropyl Methylcellulose Phthalate | 256 |
| Carboxymethylcellulose Calcium | 85 | Imidurea | 261 |
| Carboxymethylcellulose Sodium | 87 | Isopropyl Alcohol | 263 |
| Carrageenan | 91 | Isopropyl Myristate | 265 |
| Castor Oil, Hydrogenated | 94 | Isopropyl Palmitate | 267 |
| Cellulose Acetate | 96 | Kaolin | 269 |
| Cellulose Acetate Phthalate | 99 | Lactic Acid | 272 |
| Cellulose, Microcrystalline | 102 | Lactitol | 274 |
| Cellulose, Powdered | 107 | Lactose | 276 |
| Cellulose, Silicified Microcrystalline | 110 | Lanolin | 286 |
| Cetostearyl Alcohol | 112 | Lanolin Alcohols | 288 |
| Cetrimide | 114 | Lanolin, Hydrous | 290 |
| Cetyl Alcohol | 117 | Lecithin | 292 |
| Chlorhexidine | 121 | Magnesium Aluminum Silicate | 295 |
| Chlorobutanol | 126 | Magnesium Carbonate | 299 |
| Chlorocresol | 129 | Magnesium Oxide | 303 |
| Chlorodifluoroethane (HCFC) | 132 | Magnesium Stearate | 305 |
| Chlorofluorocarbons (CFC) | 134 | Magnesium Trisilicate | 309 |

| | | | |
|--|-----|--|-----|
| Malic Acid | 311 | Sodium Ascorbate | 468 |
| Maltitol | 313 | Sodium Benzoate | 471 |
| Maltitol Solution | 315 | Sodium Bicarbonate | 474 |
| Maltodextrin | 317 | Sodium Chloride | 478 |
| Maltol | 320 | Sodium Citrate Dihydrate | 482 |
| Maltose | 322 | Sodium Cyclamate | 485 |
| Mannitol | 324 | Sodium Lauryl Sulfate | 487 |
| Medium Chain Triglycerides | 329 | Sodium Metabisulfite | 490 |
| Meglumine | 332 | Sodium Phosphate, Dibasic | 493 |
| Menthol | 334 | Sodium Phosphate, Monobasic | 496 |
| Methylcellulose | 336 | Sodium Propionate | 498 |
| Methylparaben | 340 | Sodium Starch Glycolate | 501 |
| Mineral Oil | 345 | Sodium Stearyl Fumarate | 505 |
| Mineral Oil, Light | 347 | Sorbic Acid | 508 |
| Mineral Oil and Lanolin Alcohols | 349 | Sorbitan Esters (Sorbitan Fatty Acid Esters) | 511 |
| Monoethanolamine | 350 | Sorbitol | 515 |
| Nitrogen | 352 | Soybean Oil | 519 |
| Nitrous Oxide | 354 | Starch | 522 |
| Oleic Acid | 356 | Starch, Pregelatinized | 528 |
| Paraffin | 358 | Starch, Sterilizable Maize | 531 |
| Peanut Oil | 360 | Stearic Acid | 534 |
| Petrolatum | 362 | Stearyl Alcohol | 537 |
| Petrolatum and Lanolin Alcohols | 365 | Sucrose | 539 |
| Phenol | 367 | Sugar, Compressible | 544 |
| Phenoxyethanol | 370 | Sugar, Confectioner's | 546 |
| Phenylethyl Alcohol | 372 | Sugar Spheres | 548 |
| Phenylmercuric Acetate | 374 | Suppository Bases, Hard Fat | 550 |
| Phenylmercuric Borate | 377 | Talc | 555 |
| Phenylmercuric Nitrate | 379 | Tartaric Acid | 558 |
| Polacrilin Potassium | 383 | Tetrafluoroethane (HFC) | 560 |
| Poloxamer | 386 | Thimerosal | 562 |
| Polydextrose | 389 | Titanium Dioxide | 565 |
| Polyethylene Glycol | 392 | Tragacanth | 568 |
| Polyethylene Oxide | 399 | Triacetin | 570 |
| Polymethacrylates | 401 | Triethanolamine | 572 |
| Polyoxyethylene Alkyl Ethers | 407 | Triethyl Citrate | 574 |
| Polyoxyethylene Castor Oil Derivatives | 412 | Vanillin | 576 |
| Polyoxyethylene Sorbitan Fatty Acid Esters | 416 | Vegetable Oil, Hydrogenated, Type I | 578 |
| Polyoxyethylene Stearates | 420 | Water | 580 |
| Polyvinyl Alcohol | 424 | Wax, Anionic Emulsifying | 585 |
| Potassium Chloride | 426 | Wax, Carnauba | 587 |
| Potassium Citrate | 429 | Wax, Cetyl Esters | 589 |
| Potassium Sorbate | 431 | Wax, Microcrystalline | 591 |
| Povidone | 433 | Wax, Nonionic Emulsifying | 593 |
| Propylene Carbonate | 440 | Wax, White | 595 |
| Propylene Glycol | 442 | Wax, Yellow | 597 |
| Propylene Glycol Alginate | 445 | Xanthan Gum | 599 |
| Propyl Gallate | 447 | Xylitol | 602 |
| Propylparaben | 450 | Zein | 606 |
| Saccharin | 454 | Zinc Stearate | 608 |
| Saccharin Sodium | 457 | | |
| Sesame Oil | 460 | <i>Appendix I: Suppliers' Directory</i> | 611 |
| Shellac | 462 | <i>Appendix II: HPE Laboratory Methods</i> | 641 |
| Sodium Alginate | 465 | <i>Index</i> | 645 |

Related Substances

Acetyltributyl Citrate
 Acetyltriethyl Citrate
 Aleuritic Acid
d-Alpha Tocopherol
d-Alpha Tocopheryl Acetate
dl-Alpha Tocopheryl Acetate
d-Alpha Tocopheryl Acid Succinate
dl-Alpha Tocopheryl Acid Succinate
 Amylopectin
 α -Amylose
 Anhydrous Citric Acid
 Anhydrous Sodium Citrate
 Anhydrous Sodium Propionate
 Bacteriostatic Water for Injection
 Bentonite Magma
 Beta-Carotene
 Beta-Tocopherol
 Butylparaben Sodium
 Calcium Alginate
 Calcium Ascorbate
 Calcium Cyclamate
 Calcium Propionate
 Calcium Silicate
 Calcium Sorbate
 Calcium Sulfate Hemihydrate
 Carbon Dioxide-Free Water
 Carboxymethylcellulose Sodium 12
 Castor Oil
 Cationic Emulsifying Wax
 Chlorhexidine Acetate
 Chlorhexidine Gluconate
 Chlorhexidine Hydrochloride
 Chlorodifluoromethane
 Chlorophenoxyethanol
 Chloroxylenol
 Corn Syrup Solids
m-Cresol
o-Cresol
p-Cresol
 Cyclamic Acid
 Dehydrated Alcohol
 Delta-Tocopherol
 Denatured Alcohol
 Dextrose Anhydrous
 Diazolidinyl Urea
 Dibasic Sodium Phosphate
 Dibutyl Phthalate
 Dilute Alcohol
 Dilute Hydrochloric Acid
 Dimethyl- β -Cyclodextrin
 Dimethyl Phthalate
 Dipotassium Edetate
 Disodium Edetate
 Docusate Calcium
 Docusate Potassium
 Dodecyl Gallate
 Dodecyltrimethylammonium Bromide
 Edetate Calcium Disodium
 Eglumine
 Ethyl Gallate
 Ethylparaben Potassium
 Ethylparaben Sodium
 Fructose Liquid
 Fructose Milled
 Fructose Pyrogen-Free
 Gamma-Tocopherol
 Glyceryl Behenate
 Hard Water
 Hexadecyltrimethylammonium Bromide
 High Fructose Syrup
 Hydrogenated Vegetable Oil, Type II
 2-Hydroxyethyl- β -Cyclodextrin
 2-Hydroxypropyl- β -Cyclodextrin
 Indigo Carmine
 Invert Sugar
 Iron Oxides
 Liquified Phenol
 Magnesium Carbonate Anhydrous
 Magnesium Carbonate Hydroxide
 Magnesium Lauryl Sulfate
 Magnesium Silicate
 Magnesium Trisilicate Anhydrous
 D-Malic Acid
 L-Malic Acid
d-Menthol
l-Menthol
 Methyl Methacrylate
 Methyl Oleate
 Methylparaben Potassium
 Methylparaben Sodium
 Microcrystalline Cellulose and Carboxymethylcellulose Sodium
 Monobasic Potassium Phosphate
 Montmorillonite
 Normal Magnesium Carbonate
 Octyl Gallate
 Palmitic Acid
 Pharmaceutical Glaze
 Phenoxypropanol
 Polacrilin
 Poly (Methyl Methacrylate)
 Potassium Alginate
 Potassium Benzoate
 Potassium Bicarbonate
 Potassium Bisulfite
 Potassium Citrate Anhydrous
 Potassium Metabisulfite
 Potassium Propionate
 Powdered Fructose
 Propan-1-ol
 Propionic Acid
 (*S*)-Propylene Carbonate
 Propylparaben Potassium
 Propylparaben Sodium
 Purified Stearic Acid
 Rapeseed Oil
 Saccharin Ammonium
 Saccharin Calcium
 Saponite

xiv Related Substances

Self-emulsifying Glyceryl Monostearate
Shellolic Acid
Sodium Bisulfite
Sodium Edetate
Sodium Sorbate
Sodium Sulfite
Soft Water
Sorbitol Solution 70%
Spermaceti Wax
Sterile Water for Inhalation
Sterile Water for Injection
Sterile Water for Irrigation
Sugartab
Sunset Yellow FCF

Synthetic Paraffin
D-(-)-Tartaric Acid
DL-(±)-Tartaric Acid
Tartrazine
Theobroma Oil
Tocopherols Excipients
Tribasic Sodium Phosphate
Tributyl Citrate
Trimethyl-β-Cyclodextrin
Trimethyltetradecylammonium Bromide
Trisodium Edetate
Water for Injection
White Petrolatum
Zinc Propionate

Benzalkonium Chloride

1. Nonproprietary Names

BP: Benzalkonium chloride
 JP: Benzalkonium chloride
 PhEur: Benzalkonii chloridum
 USP: Benzalkonium chloride

2. Synonyms

Alkylbenzyltrimethylammonium chloride; alkyl dimethyl benzyl ammonium chloride; BKC; *Catigene DC 100*; *Exameen 3580*; *Hyamine 3500*; *Pentonium*; *Roccal*; *Zephiran*.

3. Chemical Name and CAS Registry Number


Alkyldimethyl(phenylmethyl)ammonium chloride [8001-54-5]

4. Empirical Formula Molecular Weight

The USP describes benzalkonium chloride as a mixture of alkylbenzyltrimethylammonium chlorides of the general formula $[C_6H_5CH_2N(CH_3)_2R]Cl$, where R represents a mixture of alkyls, including all or some of the group beginning with $n-C_8H_{17}$ and extending through higher homologs, with $n-C_{12}H_{25}$, $n-C_{14}H_{29}$, and $n-C_{16}H_{33}$ comprising the major portion.

The average molecular weight of benzalkonium chloride is 360.

5. Structural Formula



R = mixture of alkyls: $n-C_8H_{17}$ to $n-C_{18}H_{37}$; mainly $n-C_{12}H_{25}$ (dodecyl), $n-C_{14}H_{29}$ (tetradecyl), and $n-C_{16}H_{33}$ (hexadecyl).

6. Functional Category

Antimicrobial preservative; antiseptic; disinfectant; solubilizing agent; wetting agent.

7. Applications in Pharmaceutical Formulation or Technology

Benzalkonium chloride is a quaternary ammonium compound used in pharmaceutical formulations as an antimicrobial preservative in applications similar to other cationic surfactants, such as cetrimide.

In ophthalmic preparations, benzalkonium chloride is one of the most widely used preservatives, at a concentration of 0.01-0.02% w/v. Often it is used in combination with other preservatives or excipients, particularly 0.1% w/v disodium

edetate, to enhance its antimicrobial activity against strains of *Pseudomonas*.

In nasal and otic formulations a concentration of 0.002-0.02% is used, sometimes in combination with 0.002-0.005% w/v thimerosal. Benzalkonium chloride 0.01% w/v is also employed as a preservative in small-volume parenteral products.

Benzalkonium chloride is additionally used as a preservative in cosmetics.

8. Description

Benzalkonium chloride occurs as a white or yellowish-white amorphous powder, a thick gel, or gelatinous flakes. It is hygroscopic, soapy to the touch, and has a mild aromatic odor and very bitter taste.

9. Pharmacopeial Specifications

| Test | JP | PhEur | USP |
|--|-------------|-------------|-------------|
| Identification | + | + | + |
| Characters | — | + | — |
| Acidity or alkalinity | — | + | — |
| Appearance of solution | + | + | — |
| Water | ≤ 15.0% | ≤ 10.0% | ≤ 15.0% |
| Residue on ignition | ≤ 0.2% | — | ≤ 2.0% |
| Sulfated ash | — | ≤ 0.1% | — |
| Water-insoluble matter | — | — | + |
| Foreign amines | — | + | + |
| Ratio of alkyl components | — | — | + |
| Assay (dried basis) | | | |
| Of $n-C_{12}H_{25}$ | — | — | ≥ 40.0% |
| Of $n-C_{14}H_{29}$ | — | — | ≥ 20.0% |
| Of $n-C_{12}H_{25}$ & $n-C_{14}H_{29}$ | — | — | ≥ 70.0% |
| For total alkyl content | 95.0-105.0% | 95.0-104.0% | 97.0-103.0% |

10. Typical Properties

Acidity/alkalinity: pH = 5-8 for a 10% w/v aqueous solution.

Antimicrobial activity: benzalkonium chloride solutions are active against a wide range of bacteria, yeasts, and fungi. Activity is more marked against Gram-positive than Gram-negative bacteria and minimal against bacterial endospores and acid-fast bacteria. The antimicrobial activity of benzalkonium chloride is significantly dependent upon the alkyl composition of the homolog mixture.⁽¹⁾ Benzalkonium chloride is ineffective against some *Pseudomonas aeruginosa* strains, *Mycobacterium tuberculosis*, *Trichophyton interdigitale*, and *T. rubrum*. However, combined with disodium edetate (0.01-0.1% w/v), benzyl alcohol, phenylethanol, or phenylpropanol, the activity against *Pseudomonas aeruginosa* is increased.⁽²⁾ Antimicrobial activity may also be enhanced by the addition of phenylmercuric acetate, phenylmercuric borate, chlorhexidine, cetrimide, or *m*-cresol.^(3,4) In the presence of citrate and phosphate buffers (but not borate), activity against *Pseudomonas* can be reduced. *See also* Sections 11 and 12. Benzalkonium chloride is relatively inactive against spores and molds, but is active against some viruses, including HIV.⁽⁵⁾ Inhibitory activity increases with pH although antimicrobial activity occurs between pH 4-10. Typical minimum inhibitory concentrations (MICs) are shown in Table I.

Table I: Minimum inhibitory concentrations (MICs) of benzalkonium chloride.

| Microorganism | MIC ($\mu\text{g/mL}$) |
|---------------------------------|--------------------------|
| <i>Aerobacter aerogenes</i> | 64 |
| <i>Clostridium histolyticum</i> | 5 |
| <i>Clostridium oedematiens</i> | 5 |
| <i>Clostridium tetani</i> | 5 |
| <i>Clostridium welchii</i> | 5 |
| <i>Escherichia coli</i> | 16 |
| <i>Pneumococcus II</i> | 5 |
| <i>Proteus vulgaris</i> | 64 |
| <i>Pseudomonas aeruginosa</i> | 30 |
| <i>Salmonella enteritidis</i> | 30 |
| <i>Salmonella paratyphi</i> | 16 |
| <i>Salmonella typhosa</i> | 4 |
| <i>Shigella dysenteriae</i> | 2 |
| <i>Staphylococcus aureus</i> | 1.25 |
| <i>Streptococcus pyrogenes</i> | 1.25 |
| <i>Vibrio cholerae</i> | 2 |

Density: $\approx 0.98 \text{ g/cm}^3$ at 20°C

Melting point: $\approx 40^\circ\text{C}$

Partition coefficients: the octanol: water partition coefficient varies with the alkyl chain length of the homolog; 9.98 for C_{12} , 32.9 for C_{14} , and 82.5 for C_{16} .

Solubility: practically insoluble in ether; very soluble in acetone, ethanol (95%), methanol, propanol, and water. Aqueous solutions of benzalkonium chloride foam when shaken, have a low surface tension and possess detergent and emulsifying properties.

11. Stability and Storage Conditions

Benzalkonium chloride is hygroscopic and may be affected by light, air, and metals.

Solutions are stable over a wide pH and temperature range and may be sterilized by autoclaving without loss of effectiveness. Solutions may be stored for prolonged periods at room temperature. Dilute solutions stored in polyvinyl chloride or polyurethane foam containers may lose antimicrobial activity.

The bulk material should be stored in an airtight container, protected from light and contact with metals, in a cool, dry, place.

12. Incompatibilities

Incompatible with aluminum, anionic surfactants, citrates, cotton, fluorescein, hydrogen peroxide, hydroxypropyl methylcellulose,⁽⁶⁾ iodides, kaolin, lanolin, nitrates, nonionic surfactants in high concentration, permanganates, protein, salicylates, silver salts, soaps, sulfonamides, tartrates, zinc oxide, zinc sulfate, some rubber mixes, and some plastic mixes.

Benzalkonium chloride has been shown to be adsorbed to various filtering membranes especially those that are hydrophobic or anionic.⁽⁷⁾

13. Method of Manufacture

Benzalkonium chloride is formed by the reaction of a solution of *N*-alkyl-*N*-methyl-benzamine with methyl chloride in an organic solvent suitable for precipitating the quaternary compound as it is formed.

14. Safety

Benzalkonium chloride is usually nonirritating, nonsensitizing, and well tolerated in the dilutions normally employed on the skin and mucous membranes. However, benzalkonium chloride has been associated with adverse effects when used in some pharmaceutical formulations.⁽⁸⁾

Ototoxicity can occur when benzalkonium chloride is applied to the ear⁽⁹⁾ and prolonged contact with the skin can occasionally cause irritation and hypersensitivity. Benzalkonium chloride is also known to cause bronchoconstriction in some asthmatics when used in nebulizer solutions.⁽¹⁰⁻¹⁴⁾

Toxicity experiments with rabbits have shown benzalkonium chloride, in concentrations higher than that normally used as a preservative, to be harmful to the eye. However, the human eye appears to be less affected than the rabbit eye and many ophthalmic products have been formulated with benzalkonium chloride 0.01% w/v as the preservative. Benzalkonium chloride is not suitable for use as a preservative in solutions used for storing and washing hydrophilic soft contact lenses, as the benzalkonium chloride can bind to the lenses and may later produce ocular toxicity when the lenses are worn.⁽¹⁵⁾ Solutions stronger than 0.03% w/v concentration entering the eye require prompt medical attention.

Local irritation of the throat, esophagus, stomach, and intestine can occur following contact with strong solutions ($> 0.1\%$ w/v). The fatal oral dose of benzalkonium chloride in humans is estimated to be 1-3 g. Adverse effects following oral ingestion include vomiting, collapse, and coma. Toxic doses lead to paralysis of the respiratory muscles, dyspnea, and cyanosis.

LD₅₀ (guinea pig, oral): 200 mg/kg⁽¹⁶⁾

LD₅₀ (mouse, IP): 10 mg/kg

LD₅₀ (mouse, IV): 10 mg/kg

LD₅₀ (mouse, oral): 175 mg/kg

LD₅₀ (mouse, SC): 64 mg/kg

LD₅₀ (rat, IP): 14.5 mg/kg

LD₅₀ (rat, IV): 13.9 mg/kg

LD₅₀ (rat, oral): 240 mg/kg

LD₅₀ (rat, SC): 400 mg/kg

LD₅₀ (rat, skin): 1.56 g/kg

15. Handling Precautions

Observe normal precautions appropriate to the circumstances and quantity of material handled. Benzalkonium chloride is irritant to the skin and eyes and repeated exposure to the skin may cause hypersensitivity. Concentrated benzalkonium chloride solutions accidentally spilled on the skin may produce corrosive skin lesions with deep necrosis and scarring, and should be washed immediately with water, followed by soap solutions applied freely. Gloves, eye protection, and suitable protective clothing should be worn.

16. Regulatory Status

Included in the FDA Inactive Ingredients Guide (inhalations, IM injections, nasal, ophthalmic, otic, and topical preparations). Included in nonparenteral medicines licensed in the UK.

17. Pharmacopeias

Eur, Int, Jpn, Pol, and US.

18. Related Substances

Benzethonium chloride; cetrimide.

19. Comments**20. Specific References**

1. Euerby MR. High performance liquid chromatography of benzalkonium chlorides - variation in commercial preparations. *J Clin Hosp Pharm* 1985; 10: 73-77.
2. Richards RME, McBride RJ. Enhancement of benzalkonium chloride and chlorhexidine acetate activity against *Pseudomonas aeruginosa* by aromatic alcohols. *J Pharm Sci* 1973; 62: 2035-2037.
3. Hugbo PG. Additivity and synergism *in vitro* as displayed by mixtures of some commonly employed antibacterial preservatives. *Can J Pharm Sci* 1976; 11: 17-20.
4. McCarthy TJ, Myburgh JA, Butler N. Further studies on the influence of formulation on preservative activity. *Cosmet Toilet* 1977; 92(3): 33-36.
5. Chermann JC, Barre-Sinoussi F, Henin Y, Marechal V. HIV inactivation by a spermicide containing benzalkonium. *AIDS Forsch* 1987; 2: 85-86.
6. Richards RME. Effect of hypromellose on the antibacterial activity of benzalkonium chloride. *J Pharm Pharmacol* 1976; 28: 264.
7. Bin T, Kulshreshtha AK, Al-Shakhshir R, Hem SL. Adsorption of benzalkonium chloride by filter membranes: mechanisms and effect of formulation and processing parameters. *Pharm Dev Technol* 1999; 4(2), 151-165.
8. Smolinske SC. *Handbook of Food, Drug, and Cosmetic Excipients*. Boca Raton, FL, CRC Press Inc, 1992; 31-39.
9. Honigman JL. Disinfectant ototoxicity [letter]. *Pharm J* 1975; 215: 523.
10. Beasley CRW, Rafferty P, Holgate ST. Bronchoconstrictor properties of preservatives in ipratropium bromide (Atrovent) nebuliser solution. *Br Med J* 1987; 294: 1197-1198.
11. Miszkiel KA, Beasley R, Rafferty P, Holgate ST. The contribution of histamine release to bronchoconstriction provoked by inhaled benzalkonium chloride in asthma. *Br J Clin Pharmacol* 1988; 25: 157-163.
12. Miszkiel KA, Beasley R, Holgate ST. The influence of ipratropium bromide and sodium cromoglycate on benzalkonium chloride-induced bronchoconstriction in asthma. *Br J Clin Pharmacol* 1988; 26: 295-301.

13. Worthington I. Bronchoconstriction due to benzalkonium chloride in nebulizer solutions. *Can J Hosp Pharm* 1989; 42: 165-166.
14. Boucher M, Roy MT, Henderson J. Possible association of benzalkonium chloride in nebulizer solutions with respiratory arrest. *Ann Pharmacother* 1992; 26: 772-774.
15. Gasset AR. Benzalkonium chloride toxicity to the human cornea. *Am J Ophthalmol* 1977; 84: 169-171.
16. Sweet DV, editor. Registry of Toxic Effects of Chemical Substances. Cincinnati, US Department of Health, 1987

21. General References

- Cowen RA, Steiger B. Why a preservative system must be tailored to a specific product. *Cosmet Toilet* 1977; 92(3): 15-20.
- El-Falaha BMA, Rogers DT, Furr JR, Russell AD. Surface changes in *Pseudomonas aeruginosa* exposed to chlorhexidine diacetate and benzalkonium chloride. *Int J Pharmaceutics* 1985; 23: 239-243.
- El-Falaha BMA, Russell AD, Furr JR, Rogers DT. Activity of benzalkonium chloride and chlorhexidine diacetate against wild-type and envelope mutants of *Escherichia coli* and *Pseudomonas aeruginosa*. *Int J Pharmaceutics* 1985; 23: 239-243.
- Karabit MS, Juneskans OT, Lundgren P. Studies on the evaluation of preservative efficacy III: the determination of antimicrobial characteristics of benzalkonium chloride. *Int J Pharmaceutics* 1988; 46: 141-147.
- Lien EJ, Perrin JH. Effect of chain length on critical micelle formation and protein binding of quaternary ammonium compounds. *J Med Chem* 1976; 19: 849-850.
- Martin AR. Anti-infective agents. In: Doerge RF, editor. *Wilson and Gisvold's Textbook of Organic, Medicinal and Pharmaceutical Chemistry*. Philadelphia, J.B. Lippincott Company, 1982; 141-142.
- Pensé AM, Vauthier C, Puisieux F, Benoit JP. Microencapsulation of benzalkonium chloride. *Int J Pharmaceutics* 1992; 81: 111-117.
- Prince HN, Nonemaker WS, Norgard RC, Prince DL. Drug resistance studies with topical antiseptics. *J Pharm Sci* 1978; 67: 1629-1631.
- Wallhäuser KH. Benzalkonium chloride. In: Kabara JJ, editor. *Cosmetic and Drug Preservation Principles and Practice*. New York, Marcel Dekker Inc, 1984; 731-734.

22. Authors

AH Kibbe.

Carboxymethylcellulose Sodium

1. Nonproprietary Names

BP: Carmellose sodium
 JP: Carmellose sodium
 PhEur: Carboxymethylcellulosum natricum
 USP: Carboxymethylcellulose sodium

2. Synonyms

Akucell; Aquasorb; Blanose; Cekol; cellulose gum; CMC sodium; E466; Finifix; Nymcel; SCMC; sodium carboxymethylcellulose; sodium cellulose glycolate; sodium CMC; Tylose CB.


3. Chemical Name and CAS Registry Number

Cellulose, carboxymethyl ether, sodium salt [9004-32-4]

4. Empirical Formula Molecular Weight

The USP describes carboxymethylcellulose sodium as the sodium salt of a polycarboxymethyl ether of cellulose. Typical molecular weight is 90 000-700 000.

5. Structural Formula



Structure shown with a degree of substitution (DS) of 1.0.

6. Functional Category

Coating agent; tablet and capsule disintegrant; tablet binder; stabilizing agent; suspending agent; viscosity-increasing agent; water absorbing agent.

7. Applications in Pharmaceutical Formulation or Technology

Carboxymethylcellulose sodium is widely used in oral and topical pharmaceutical formulations primarily for its viscosity-increasing properties. Viscous aqueous solutions are used to suspend powders intended for either topical application or oral and parenteral administration.⁽¹⁾ Carboxymethylcellulose sodium may also be used as a tablet binder and disintegrant,⁽²⁻⁴⁾ and to stabilize emulsions.⁽⁵⁾

Higher concentrations, usually 3-6%, of the medium viscosity grade is used to produce gels which can be used as the base for applications and pastes; glycols are often included in such gels to prevent drying out. Carboxymethylcellulose sodium is additionally one of the main ingredients of self-adhesive ostomy, wound care, and dermatological patches where it is used to absorb wound exudate or transepidermal water and sweat.

Carboxymethylcellulose sodium is also used in cosmetics, toiletries,⁽⁶⁾ incontinence, personal hygiene, and food products.

| Use | Concentration (%) |
|-------------------|-------------------|
| Emulsifying agent | 0.25-1.0 |
| Gel-forming agent | 3.0-6.0 |
| Injections | 0.05-0.75 |
| Oral solutions | 0.1-1.0 |
| Tablet binder | 1.0-6.0 |

8. Description

Carboxymethylcellulose sodium occurs as a white to almost white colored, odorless, granular powder. *See also* Section 19.

9. Pharmacopeial Specifications

| Test | JP | PhEur | USP |
|-----------------------------|----------|------------|------------|
| Identification | + | + | + |
| Characters | + | + | — |
| pH (1% w/v solution) | 6.0-8.0 | 6.0-8.0 | 6.5-8.5 |
| Degree of substitution | — | — | 1.15-1.45 |
| Appearance of solution | + | + | — |
| Viscosity | + | + | + |
| Loss on drying | ≤ 10.0% | ≤ 10.0% | ≤ 10.0% |
| Heavy metals | ≤ 20 ppm | ≤ 20 ppm | ≤ 20 ppm |
| Chloride | ≤ 0.640% | ≤ 0.25% | — |
| Arsenic | ≤ 10 ppm | — | — |
| Sulfate | ≤ 0.960% | — | — |
| Silicate | ≤ 0.5% | — | — |
| Sodium glycolate | — | ≤ 0.4% | ≤ 0.5% |
| Starch | + | — | — |
| Sulfated ash | — | 20.0-33.3% | — |
| Organic volatile impurities | — | — | + |
| Assay (of sodium) | 6.5-8.5% | 6.5-10.8% | 10.5-12.0% |

10. Typical Properties

Compaction data: See Fig. 1.^(a)

Density (bulk): 0.520 g/cm³

Density (tapped): 0.783 g/cm³

Dissociation constant: pK_a = 4.30

Melting point: browns at approximately 227°C, chars at approximately 252°C.

Moisture content: typically, contains less than 10% of water.

However, carboxymethylcellulose sodium is hygroscopic and absorbs significant amounts of water at temperatures up to 37°C at relative humidities of about 80%. *See* Section 11. *See also* Fig. 2.^(a)

Solubility: practically insoluble in acetone, ethanol, ether, and toluene. Easily dispersed in water at all temperatures, forming clear, colloidal solutions. The aqueous solubility varies with the degree of substitution (DS). See Section 19.

SEM: 1

Excipient: Carboxymethylcellulose sodium
 Manufacturer: Buckeye Cellulose Corp
 Lot No: 9247 AP
 Magnification: 120x
 Voltage: 10 kV



SEM: 2

Excipient: Carboxymethylcellulose sodium
 Manufacturer: Hercules Ltd
 Lot No: 21 A-1 (44390)
 Magnification: 600x
 Voltage: kV





Fig. 1: Heckel plot carboxymethylcellulose sodium.

○ : ln1/(1-D)
 ■ : Hardness

Viscosity: various grades of carboxymethylcellulose sodium are commercially available which have differing aqueous viscosities; aqueous 1% w/v solutions with viscosities of 5-13 000 mPa s (5-13 000 cP) may be obtained. An increase in concentration results in an increase in aqueous solution viscosity.⁽⁶⁾ Prolonged heating at high temperatures will depolymerize the gum and permanently decrease




Fig. 2: Sorption-desorption isotherm of carboxymethylcellulose sodium.

○ : Sorption
 ■ : Desorption

the viscosity. The viscosity of sodium carboxymethylcellulose solutions is fairly stable over a pH range of 4 to 10. The optimum pH range is neutral. Viscosities of three grades of sodium carboxymethylcellulose are shown in Table 1. See also Section 11.

^(a) Results of laboratory project for third edition.

Table I: Viscosity of aqueous carboxymethylcellulose sodium solutions^(a) (Measurements taken with a Brookfield LVT viscometer at 25°C).

| | Grade | Concen. (% w/v) | Viscosity (mPa s) | Spindle | Speed |
|---------------------|--------------------|--------------------|----------------------|---------|--------|
| Low viscosity | Akucell AF 0305 | 1% | 10-15 | #1 | 60 rpm |
| Medium viscosity | Akucell AF 2785 | 1% | 1500-2500 | #3 | 30 rpm |
| High viscosity | Akucell AF 3085 | 1% | 8000-1200 | #4 | 30 rpm |

^(a) Ashland Chemical Company technical literature.

11. Stability and Storage Conditions

Carboxymethylcellulose sodium is a stable, though hygroscopic material. Under high humidity conditions carboxymethylcellulose sodium can absorb a large quantity (> 50%) of water. In tablets, this has been associated with a decrease in tablet hardness and an increase in disintegration time.⁽⁷⁾

Aqueous solutions are stable between pH 2-10; below pH 2 precipitation can occur while above pH 10 solution viscosity rapidly decreases. Generally, solutions exhibit maximum viscosity and stability at pH 7-9.

Carboxymethylcellulose sodium may be sterilized in the dry state by maintaining it at a temperature of 160°C for 1 hour. However, this process results in a significant decrease in viscosity and some deterioration in the properties of solutions prepared from the sterilized material.

Aqueous solutions may similarly be sterilized by heating although this also results in some reduction in viscosity. After autoclaving, viscosity is reduced by about 25% although this reduction is less marked than for solutions prepared from material sterilized in the dry state. The extent of the reduction is dependent on the molecular weight and degree of substitution; higher molecular weight grades generally undergo a greater percentage reduction in viscosity. Sterilization of solutions by gamma irradiation also results in a reduction in viscosity.

Aqueous solutions stored for prolonged periods should contain an antimicrobial preservative.⁽⁸⁾

The bulk material should be stored in a well-closed container in a cool, dry, place.

12. Incompatibilities

Carboxymethylcellulose sodium is incompatible with strongly acidic solutions and with the soluble salts of iron and some other metals, such as aluminum, mercury, and zinc. Precipitation can occur at pH < 2 and when mixed with ethanol (95%).

Carboxymethylcellulose sodium also forms complex coacervates with gelatin and pectin. It additionally forms a complex with collagen and is capable of precipitating certain positively charged proteins.

13. Method of Manufacture

Alkali cellulose is prepared by steeping cellulose obtained from wood pulp or cotton fibers in sodium hydroxide solution. The alkali cellulose is then reacted with sodium monochloroacetate to produce carboxymethylcellulose sodium. Sodium chloride and sodium glycolate are obtained as by-products of this etherification.

14. Safety

Carboxymethylcellulose sodium is used in oral, topical, and some parenteral formulations. It is also widely used in cosmetics, toiletries, and food products and is generally regarded as a nontoxic and nonirritant material. However, oral consumption of large amounts of carboxymethylcellulose sodium can have a laxative effect; therapeutically, 4-10 g in daily divided doses of the medium and high viscosity grades of carboxymethylcellulose sodium have been used as bulk laxatives.

The WHO has not specified an acceptable daily intake for carboxymethylcellulose sodium as a food additive since the levels necessary to achieve a desired effect were not considered to be a hazard to health.⁽⁹⁾ It is listed as a substance that may be added to all foodstuffs in the European Council Directive No 95/2/EC.⁽¹⁰⁾

In animal studies, subcutaneous administration of carboxymethylcellulose sodium has been found to cause inflammation and in some cases of repeated injection fibrosarcomas have been found at the injection site.⁽¹¹⁾

Hypersensitivity and anaphylactic reactions have occurred in cattle and horses which have been attributed to carboxymethylcellulose sodium in parenteral formulations such as vaccines and penicillins.^(12,13)

LD₅₀ (guinea pig, oral): 16 g/kg⁽¹⁴⁾

LD₅₀ (mouse, oral): > 27 g/kg

LD₅₀ (rabbit, oral): > 27 g/kg

LD₅₀ (rat, oral): 27 g/kg

15. Handling Precautions

Observe normal precautions appropriate to the circumstances and quantity of material handled. Carboxymethylcellulose sodium may be irritant to the eyes. Eye protection is recommended.

16. Regulatory Status

GRAS listed. Accepted as a food additive in Europe. Included in the FDA Inactive Ingredients Guide (dental preparations, inhalations, intra-articular, intrabursal, intradermal, intraleisional, IM, intrasynovial and SC injections, oral capsules, drops, solutions, suspensions, syrups and tablets, topical, and vaginal preparations). Included in nonparenteral medicines licensed in the UK.

17. Pharmacopeias

Eur, Int, Jpn, Pol, and US.

18. Related Substances

Carboxymethylcellulose calcium; carboxymethylcellulose sodium 12; croscarmellose sodium.

Carboxymethylcellulose sodium 12

Pharmacopeias: US.

Comments: carboxymethylcellulose sodium 12 is the sodium salt of a polycarboxymethyl ether of cellulose. Its degree of substitution is between 1.15-1.45, corresponding to a sodium content, calculated on the dry basis, of 10.5-12.0%.

19. Comments

A number of grades of carboxymethylcellulose sodium are commercially available, with a degree of substitution (DS) in the range of 0.7 to 1.2. The DS is defined as the average

number of hydroxyl groups substituted per anhydroglucose unit and it is this which determines the aqueous solubility of the polymer. Thermal crosslinking reduces solubility while retaining water absorption therefore producing materials suitable for water absorption.

Grades are typically classified as being either low, medium, or high viscosity. The degree of substitution and the maximum viscosity of an aqueous solution of stated concentration should be indicated on any carboxymethylcellulose sodium labelling.

Carboxymethylcellulose sodium has been reported to give false positive results in the LAL test for endotoxins.⁽¹⁵⁾

20. Specific References

1. Hussain MA, Aungst BJ, Maurin MB, Wu LS. Injectable suspensions for prolonged release nalbuphine. *Drug Dev Ind Pharm* 1991; 17: 67-76.
2. Khan KA, Rhodes CT. Evaluation of different viscosity grades of sodium carboxymethylcellulose as tablet disintegrants. *Pharm Acta Helv* 1975; 50: 99-102.
3. Shah NH, Lazarus JH, Sheth PR, Jarowski CI. Carboxymethylcellulose: effect of degree of polymerization and substitution on tablet disintegration and dissolution. *J Pharm Sci* 1981; 70: 611-613.
4. Singh J. Effect of sodium carboxymethylcelluloses on the disintegration, dissolution and bioavailability of lorazepam tablets. *Drug Dev Ind Pharm* 1992; 18: 375-383.
5. Oza KP, Frank SG. Microcrystalline cellulose stabilized emulsions. *J Disper Sci Technol* 1986; 7(5): 543-561.
6. Mombellet H, Bale P. Sodium carboxymethylcellulose toothpaste. *Mfg Chem* 1988; 59(11): 47, 49, 52.

7. Khan KA, Rhodes CT. Water-sorption properties of tablet disintegrants. *J Pharm Sci* 1975; 64: 447-451.
8. Banker G, Peck G, Williams E, Taylor D, Pirakitikulr P. Microbiological considerations of polymer solutions used in aqueous film coating. *Drug Dev Ind Pharm* 1982; 8: 41-51.
9. FAO/WHO. Evaluation of certain food additives and contaminants. Thirty-fifth report of the joint FAO/WHO expert committee on food additives. *Tech Rep Ser Wld Hlth Org* 1990; No. 789.
10. Journal of the European Communities. European parliament and council Directive on food additives other than colours and sweeteners, No 95/2/EC Annex 1, 1995.
11. Teller MN, Brown GB. Carcinogenicity of carboxymethylcellulose in rats. *Proc Am Assoc Cancer Res* 1977; 18: 225.
12. Schneider CH, de Weck AL, Stäubli E. Carboxymethylcellulose additives in penicillins and the elucidation of anaphylactic reactions. *Experientia* 1971; 27: 167-168.
13. Aitken MM. Induction of hypersensitivity to carboxymethylcellulose in cattle. *Res Vet Sci* 1975; 19: 110-113.
14. Sweet DV, editor. Registry of Toxic Effects of Chemical Substances. Cincinnati, US Department of Health, 1987.
15. Tanaka S, Aketagawa J, Takahashi S, Shibata Y, Tsumuraya Y, Hashimoto Y. Activation of a limulus coagulation factor G by (1→3)-β-D-glucans. *Carbohydrate Res* 1991; 218: 167-174.

21. General References

- Doelker E. Cellulose derivatives. *Adv Polymer Sci* 1993; 107: 199-265.

22. Authors

D Parsons.

Cellulose, Microcrystalline

1. Nonproprietary Names

BP: Microcrystalline cellulose
JP: Microcrystalline cellulose
PhEur: Cellulosum microcrystallinum
USP: Microcrystalline cellulose

2. Synonyms

Avicel; cellulose gel; crystalline cellulose; E460; *Emcocel*; *Fibrocel*; *Tabulose*; *Vivacel*.

3. Chemical Name and CAS Registry Number


Cellulose [9004-34-6]

4. Empirical Formula and Molecular Weight

$(C_6H_{10}O_5)_n \approx 36\,000$

Where $n \approx 220$.

5. Structural Formula



6. Functional Category

Adsorbent; suspending agent; tablet and capsule diluent; tablet disintegrant.

7. Applications in Pharmaceutical Formulation or Technology


Microcrystalline cellulose is widely used in pharmaceuticals, primarily as a binder/diluent in oral tablet and capsule formulations where it is used in both wet granulation and direct-compression processes.⁽¹⁻⁷⁾ In addition to its use as a binder/diluent, microcrystalline cellulose also has some lubricant⁽⁸⁾ and disintegrant properties that make it useful in tableting.

Microcrystalline cellulose is also used in cosmetics and food products.

| Use | Concentration (%) |
|------------------------|-------------------|
| Adsorbent | 20-90 |
| Anti-adherent | 5-20 |
| Capsule binder/diluent | 20-90 |
| Tablet disintegrant | 5-15 |
| Tablet binder/diluent | 20-90 |

SEM: 1

Excipient: Microcrystalline cellulose
Manufacturer: Penwest Pharmaceuticals
Lot: 98662
Magnification: 100x



8. Description


Microcrystalline cellulose is a purified, partially depolymerized cellulose that occurs as a white, odorless, tasteless, crystalline powder composed of porous particles. It is commercially available in different particle sizes and moisture grades which have different properties and applications.

9. Pharmacopeial Specifications


| Test | JP | PhEur | USP |
|-----------------------------|----------|----------|-------------|
| Identification | + | + | + |
| Characters | + | + | — |
| pH | 5.0-7.0 | 5.0-7.5 | 5.0-7.0 |
| Bulk density | + | — | + |
| Solubility | — | + | — |
| Loss on drying | ≤ 7.0% | ≤ 6.0% | ≤ 7.0% |
| Residue on ignition | ≤ 0.05% | — | ≤ 0.05% |
| Conductivity | + | — | + |
| Sulfated ash | — | ≤ 0.1% | — |
| Ether-soluble substances | ≤ 0.05% | ≤ 0.05% | ≤ 0.05% |
| Water-soluble substances | ≤ 0.24% | ≤ 0.25% | ≤ 0.24% |
| Heavy metals | ≤ 10 ppm | ≤ 10 ppm | ≤ 0.001% |
| Starch | — | + | — |
| Organic volatile impurities | — | — | + |
| Microbial limits | + | + | + |
| Assay | — | — | 97.0-102.0% |

SEM: 2

Excipient: Microcrystalline cellulose
 Manufacturer: Penwest Pharmaceuticals
 Lot: 98662
 Magnification: 300x

**SEM: 3**

Excipient: Microcrystalline cellulose
 Manufacturer: FMC Corp
 Magnification: 100x

**10. Typical Properties**

Angle of repose: 34.4° for Emcocel 90M.⁽⁹⁾

Density (bulk):

0.337 g/cm³;^(a)

0.32 g/cm³ for Avicel PH-101;⁽¹⁰⁾

0.29 g/cm³ for Emcocel 90M.⁽⁹⁾

Density (tapped):

0.478 g/cm³;^(a)

0.45 g/cm³ for Avicel PH-101;⁽¹⁰⁾

0.35 g/cm³ for Emcocel 90M.⁽⁹⁾

Density (true): 1.512-1.668 g/cm³;^(a)

Compressibility: See Figs. 1, 2, and 3.^(a)

Mechanical properties^(a)

| | |
|---------------------------------|---------------------------|
| Compression pressure: | 9.84 kN/cm ² |
| Tensile strength: | 0.8711 kN/cm ² |
| Permanent deformation pressure: | 15.3 |
| Brittle fracture index: | 0.0821 |
| Bonding index: | 0.0571 |
| Reduced modulus of elasticity: | 1472 |

Flowability: 1.41 g/s for Emcocel 90M.⁽⁹⁾

Melting point: chars at 260-270°C.

Moisture content: typically, less than 5% w/w. However, different grades may contain varying amounts of water. Microcrystalline cellulose is hygroscopic.⁽¹¹⁾ See Fig. 4^(a) and Table I.

Particle size distribution: typical mean particle size is 20-200 µm. Different grades may have a different nominal mean particle size, see Table I.

Solubility: slightly soluble in 5% w/v sodium hydroxide solution; practically insoluble in water, dilute acids, and most organic solvents.

Specific surface area:

1.06-1.12 m²/g for Avicel PH-101.^(a)

1.21-1.30 m²/g for Avicel PH-102.^(a)

0.78-1.18 m²/g for Avicel PH-200.^(a)

^(a) Results of laboratory project for third edition.

Table I: Properties of some commercially available grades of microcrystalline cellulose.

| Grade | Nominal mean particle size (µm) | Particle Size Analysis | | Moisture content (%) |
|------------------------------|---------------------------------|------------------------|---------------------|----------------------|
| | | Mesh size | Amount retained (%) | |
| Avicel PH-101 ^(a) | 50 | 60 | ≤ 1.0 | ≤ 5.0 |
| | | 200 | ≤ 30.0 | |
| Avicel PH-102 ^(a) | 100 | 60 | ≤ 8.0 | ≤ 5.0 |
| | | 200 | ≥ 45.0 | |
| Avicel PH-103 ^(a) | 50 | 60 | ≤ 1.0 | ≤ 3.0 |
| | | 200 | ≤ 30.0 | |
| Avicel PH-105 ^(a) | 20 | 400 | ≤ 1.0 | ≤ 5.0 |
| Avicel PH-112 ^(a) | 100 | 60 | ≤ 8.0 | ≤ 1.5 |
| Avicel PH-113 ^(a) | 50 | 60 | ≤ 1.0 | ≤ 1.5 |
| | | 200 | ≤ 30.0 | |
| Avicel PH-200 ^(a) | 180 | 60 | ≥ 10.0 | ≤ 5.0 |
| | | 100 | ≥ 50.0 | |
| Avicel PH-301 ^(a) | 50 | 60 | ≤ 1.0 | ≤ 5.0 |
| | | 200 | ≤ 30.0 | |
| Avicel PH-302 ^(a) | 100 | 60 | ≤ 8.0 | ≤ 5.0 |
| | | 200 | ≥ 45.0 | |
| Emcocel 50M ^(b) | 51 | 60 | ≤ 0.25 | ≤ 5.0 |
| | | 200 | ≤ 30.0 | |
| Emcocel 90M ^(b) | 91 | 60 | ≤ 8.0 | ≤ 5.0 |
| | | 200 | ≥ 45.0 | |
| Vivacel 101 ^(c) | 50 | 50 | ≥ 35.0 | ≤ 5.0 |
| | | 150 | ≤ 10.0 | |
| Vivacel 102 ^(c) | 100 | 50 | ≥ 50.0 | ≤ 5.0 |
| | | 150 | ≤ 30.0 | |
| Vivacel 12 ^(c) | 180 | 50 | ≥ 70.0 | ≤ 5.0 |
| | | 500 | ≤ 1.0 | |
| Vivacel 20 ^(c) | 20 | 50 | ≤ 2.0 | ≤ 5.0 |
| | | 150 | ≤ 0.1 | |

Suppliers: ^(a) FMC Corporation; ^(b) Edward Mendell Co Inc; ^(c) J. Rettenmaier & Söhne GmbH




Fig. 1: Crushing strength.

(Reprinted with permission from Marcel Dekker, Inc., to be published in *Compaction of Pharmaceutical Excipients* by Metin Celik, in press, 1999.)

- : Microcrystalline cellulose, *Emcocel 90M* (Lot # 1037X, Mendell) at V = 100 mm/s
- ▲ : Microcrystalline cellulose, *Emcocel 90M* (Lot # 1037X, Mendell) at V = 300 mm/s




Fig. 2: Total work of compaction.

(Reprinted with permission from Marcel Dekker, Inc., to be published in *Compaction of Pharmaceutical Excipients* by Metin Celik, in press, 1999.)

- : Percentage porosity (E) vs. pressure plot for microcrystalline cellulose, *Emcocel 90M* (Lot # 1037X, Mendell) at V = 100 mm/s
- ▲ : Total work of compaction (TWC) vs. pressure plot for microcrystalline cellulose, *Emcocel 90M* (Lot # 1037X, Mendell) at V = 100 mm/s




Fig. 3: Heckel plot for microcrystalline cellulose.

- : ln1/(1-D)
- : Hardness




Fig. 4: Sorption-desorption isotherm for microcrystalline cellulose.

- : Sorption
- : Desorption

11. Stability and Storage Conditions

Microcrystalline cellulose is a stable, though hygroscopic material. The bulk material should be stored in a well-closed container in a cool, dry, place.

12. Incompatibilities

Incompatible with strong oxidizing agents.

13. Method of Manufacture

Microcrystalline cellulose is manufactured by the controlled hydrolysis, with dilute mineral acid solutions of α -cellulose, obtained as a pulp from fibrous plant materials. Following hydrolysis, the hydrocellulose is purified by filtration and the aqueous slurry is spray-dried to form dry, porous particles of a broad-size distribution.

14. Safety

Microcrystalline cellulose is widely used in oral pharmaceutical formulations and food products and is generally regarded as a nontoxic and nonirritant material.

Microcrystalline cellulose is not absorbed systemically following oral administration and thus has little toxic potential. Consumption of large quantities of cellulose may, however, have a laxative effect, although this is unlikely to be a problem when cellulose is used as an excipient in pharmaceutical formulations.

Deliberate abuse of formulations containing cellulose, either by inhalation or injection, has resulted in the formulation of cellulose granulomas.⁽¹²⁾

15. Handling Precautions

Observe normal precautions appropriate to the circumstances and quantity of material handled. Microcrystalline cellulose may be irritant to the eyes. Gloves, eye protection, and a dust mask are recommended. In the UK, the occupational exposure limits for cellulose has been set at 10 mg/m³ long-term (8-hour TWA) for total inhalable dust and 5 mg/m³ for respirable dust; short-term limit for total inhalable dust has been set at 20 mg/m³.⁽¹³⁾

16. Regulatory Status

GRAS listed. Accepted in Europe for use as a food additive. Included in the FDA Inactive Ingredients Guide (inhalations, oral capsules, powders, suspensions, syrups and tablets, topical, and vaginal preparations). Included in nonparenteral medicines licensed in the UK.

17. Pharmacopeias

Eur, Int, Jpn, Pol, and US.

18. Related Substances

Microcrystalline cellulose and carboxymethylcellulose sodium; powdered cellulose.

Microcrystalline cellulose and carboxymethylcellulose sodium

Synonyms: Avicel RC-581; Avicel RC-591; Avicel CL-611; colloidal cellulose; dispersible cellulose.

Appearance: white colored, odorless and tasteless hygroscopic powder.

Pharmacopeias: Br and US.

Acidity/alkalinity: pH = 6-8 for a 1.2% w/v aqueous dispersion.

Moisture content: not more than 6.0% w/w.

Particle size distribution: \leq 0.1% retained on a #60 mesh and \leq 50% retained on #325 mesh for Avicel CL-611; \leq 0.1% retained on a #60 mesh and \leq 35% retained on a #200 mesh for Avicel RC-581; \leq 0.1% retained on a #60 mesh and \leq 45% retained on a #325 mesh for Avicel RC-591.

Solubility: practically insoluble in dilute acids and organic solvents. Partially soluble in dilute alkali and water (carboxymethylcellulose sodium fraction).

Viscosity (dynamic): 5-20 mPa s (5-20 cP) for a 1.2% w/v aqueous dispersion of Avicel CL-611; 72-168 mPa s (72-168 cP) for Avicel RC-581 and 39-91 mPa s (39-91 cP) for Avicel RC-591 at the same concentration.

Comments: mixtures of microcrystalline cellulose and carboxymethylcellulose sodium that are dispersible in water and produce thixotropic gels are suitable as suspending vehicles in pharmaceutical formulations. The amount of carboxymethylcellulose present can vary between 8.3-18.8% w/w depending upon the grade of material.

19. Comments

Several different grades of microcrystalline cellulose are commercially available which differ in their method of manufacture,^(14,15) particle size, moisture, flow, and other physical properties.⁽¹⁶⁻²³⁾ The larger particle-size grades generally provide better flow properties in pharmaceutical machinery. Low-moisture grades are used with moisture-sensitive materials. Higher density grades improve flowability and weight uniformity.

20. Specific References

- Enézián GM. Direct compression of tablets using microcrystalline cellulose [in French]. *Pharm Acta Helv* 1972; 47: 321-363.
- Lerk CF, Bolhuis GK. Comparative evaluation of excipients for direct compression I. *Pharm Weekbl* 1973; 108: 469-481.
- Lerk CF, Bolhuis GK, de Boer AH. Comparative evaluation of excipients for direct compression II. *Pharm Weekbl* 1974; 109: 945-955.
- Lamberson RF, Raynor GE. Tableting properties of microcrystalline cellulose. *Mfg Chem Aerosol News* 1976; 47(6): 55-61.
- Lerk CF, Bolhuis GK, de Boer AH. Effect of microcrystalline cellulose on liquid penetration in and disintegration of directly compressed tablets. *J Pharm Sci* 1979; 68: 205-211.
- Chilamkurti RN, Rhodes CT, Schwartz JB. Some studies on compression properties of tablet matrices using a computerized instrumented press. *Drug Dev Ind Pharm* 1982; 8: 63-86.
- Wallace JW, Capozzi JT, Shangraw RF. Performance of pharmaceutical filler/binders as related to methods of powder characterization. *Pharmaceut Technol* 1983; 7(9): 94-104.
- Omay A, Omay P. Evaluation of microcrystalline cellulose as a glidant. *Indian J Pharm Sci* 1986; 48: 20-22.
- Celik M, Okutgen E. A feasibility study for the development of a prospective compaction functionality test and the establishment of a compaction data bank. *Drug Dev Ind Pharm* 1993; 19: 2309-2334.
- Parker MD, York P, Rowe RC. Binder-substrate interactions in wet granulation 3: the effect of excipient source variation. *Int J Pharmaceutics* 1992; 80: 179-190.
- Callahan JC, Cleary GW, Elefant M, Kaplan G, Kensler T, Nash RA. Equilibrium moisture content of pharmaceutical excipients. *Drug Dev Ind Pharm* 1982; 8: 355-369.
- Cooper CB, Bai TR, Heyderman E, Corrin B. Cellulose granulomas in the lungs of a cocaine sniffer. *Br Med J* 1983; 286: 2021-2022.
- Health and Safety Executive. *EH40/98: Occupational Exposure Limits 1998*. Sudbury, Health & Safety Executive, 1998.
- Jain JK, Dixit VK, Varma KC. Preparation of microcrystalline cellulose from cereal straw and its evaluation as a tablet excipient. *Indian J Pharm Sci* 1983; 45: 83-85.

15. Singla AK, Sakhuja A, Malik A. Evaluation of microcrystalline cellulose prepared from absorbent cotton as a direct compression carrier. *Drug Dev Ind Pharm* 1988; 14: 1131-1136.
16. Doelker E, Mordier D, Iten H, Humbert-Droz P. Comparative tableting properties of sixteen microcrystalline celluloses. *Drug Dev Ind Pharm* 1987; 13: 1847-1875.
17. Bassam F, York P, Rowe RC, Roberts RJ. Effect of particle size and source on variability of Young's modulus of microcrystalline cellulose powders. *J Pharm Pharmacol* 1988; 40: 68P.
18. Dittgen M, Fricke S, Gerecke H. Microcrystalline cellulose in direct tableting. *Mfg Chem* 1993; 64(7): 17, 19, 21.
19. Landin M, Martinez-Pacheco R, Gómez-Amoza JL, Souto C, Concheiro A, Rowe RC. Effect of country of origin on the properties of microcrystalline cellulose. *Int J Pharmaceutics* 1993; 91: 123-131.
20. Landin M, Martinez-Pacheco R, Gómez-Amoza JL, Souto C, Concheiro A, Rowe RC. Effect of batch variation and source of pulp on the properties of microcrystalline cellulose. *Int J Pharmaceutics* 1993; 91: 133-141.
21. Landin M, Martinez-Pacheco R, Gómez-Amoza JL, Souto C, Concheiro A, Rowe RC. Influence of microcrystalline cellulose source and batch variation on tableting behavior and

stability of prednisone formulations. *Int J Pharmaceutics* 1993; 91: 143-149.

22. Podczek F, Révész P. Evaluation of the properties of microcrystalline and microfine cellulose powders. *Int J Pharmaceutics* 1993; 91: 183-193.
23. Rowe RC, McKillop AG, Bray D. The effect of batch and source variation on the crystallinity of microcrystalline cellulose. *Int J Pharmaceutics* 1994; 101: 169-172.

21. General References

- Doelker E. Comparative compaction properties of various microcrystalline cellulose types and generic products. *Drug Dev Ind Pharm* 1993; 19: 2399-2471.
- FMC Corporation. Technical literature: *Avicel PH* microcrystalline cellulose, 1995.
- Smolinske SC. *Handbook of Food, Drug, and Cosmetic Excipients*. Boca Raton, FL, CRC Press Inc, 1992; 71-74.
- Staniforth JN, Baichwal AR, Hart JP, Heng PWS. Effect of addition of water on the rheological and mechanical properties of microcrystalline celluloses. *Int J Pharmaceutics* 1988; 41: 231-236.

22. Authors

TA Wheatley.

Dextrose

1. Nonproprietary Names

BP: Glucose
 JP: Glucose
 PhEur: Dextrosum (glucosum) monohydricum
 USP: Dextrose

2. Synonyms

Blood sugar; *Caridex*; corn sugar; D-(+)-glucopyranose monohydrate; grape sugar; starch sugar; *Tabfine D-100*.

3. Chemical Name and CAS Registry Number

D-(+)-Glucose monohydrate [5996-10-1]


See also Section 18.

4. Empirical Formula Molecular Weight

$C_6H_{12}O_6 \cdot H_2O$ 198.17 (for monohydrate)

See also Section 18.

5. Structural Formula



Anhydrous material shown.

6. Functional Category

Tablet and capsule diluent; therapeutic agent; tonicity agent; sweetening agent.

7. Applications in Pharmaceutical Formulation or Technology

Dextrose is widely used in solutions to adjust tonicity and as a sweetening agent. Dextrose is also used as a direct-compression tablet diluent and binder, primarily in chewable tablets. Although comparable as a tablet diluent to lactose, tablets produced with dextrose monohydrate require more lubrication, are less friable, and have a tendency to harden.⁽¹⁻³⁾ The mildly reducing properties of dextrose may be used when tableting to improve the stability of active materials which are sensitive to oxidation.


Dextrose is also used therapeutically and is the preferred source of carbohydrate in parenteral nutrition regimens.

8. Description

Dextrose occurs as odorless, sweet-tasting, colorless crystals or as a white crystalline or granular powder.

SEM: 1.

Excipient: Dextrose anhydrous (granular)
 Manufacturer: Mallinckrodt Speciality Chemicals Co
 Lot No.: KLKZ
 Magnification: 180x



9. Pharmacopeial Specifications

| Test | PhEur | USP |
|------------------------------|------------------|------------------|
| Identification | + | + |
| Color of solution | + | + |
| Specific rotation | +52.5° to +53.3° | +52.5° to +53.5° |
| Acidity | + | + |
| Organic volatile | — | + |
| Water | | |
| (for monohydrate) | 7.0-9.5% | 7.5-9.5% |
| (for anhydrous) | ≤ 0.5% | ≤ 1.0% |
| Residue on ignition | ≤ 0.1% | ≤ 0.1% |
| Chloride | ≤ 125 ppm | ≤ 0.018% |
| Sulfate | ≤ 200 ppm | ≤ 0.025% |
| Arsenic | ≤ 1 ppm | ≤ 1 ppm |
| Barium | ≤ 1 ppm | — |
| Calcium | ≤ 200 ppm | — |
| Heavy metals | — | ≤ 5 ppm |
| Lead | ≤ 0.5 ppm | — |
| Dextrin | + | + |
| Soluble starch, and sulfites | + | + |

10. Typical Properties

Data for dextrose monohydrate shown, see Section 18 for dextrose anhydrous data.

Acidity/alkalinity:

pH = 3.5-5.5 (20% w/v aqueous solution)

Compressibility: see Fig. 1.^(a)

Density (bulk): 0.826 g/cm^{3(b)}

Density (tapped): 1.020 g/cm^{3(b)}

Density(true): 1.54 g/cm³

Flowability: 35 g/s^(a)

Heat of solution: 105.4 J/g (25.2 cal/g)




Fig. 1: Compression characteristics of dextrose monohydrate (Staleydex).^(a)

Mean tablet weight: 502 mg
 Minimum compressional force for compaction: 4.9 kN
 Compressional force resulting in capping: 7.35 kN
 Lubricant: 0.5% w/w magnesium stearate

Hygroscopicity: anhydrous dextrose absorbs significant amounts of moisture at 25°C and a relative humidity of about 85% to form the monohydrate. The monohydrate similarly only absorbs moisture at around 85% relative humidity and 25°C. See Fig. 2.^(b)

Melting point: 83°C

Osmolarity: a 5.51% w/v aqueous solution is iso-osmotic with serum. However, it is not isotonic since dextrose can pass through the membrane of red cells and cause hemolysis.

Solubility:

| Solvent | Solubility at 20°C |
|---------------|-----------------------|
| Chloroform | Practically insoluble |
| Ethanol (95%) | 1 in 60 |
| Ether | Practically insoluble |
| Glycerin | Soluble |
| Water | 1 in 1 |

^(a) *Handbook of Pharmaceutical Excipients*, First Edition.

^(b) Results of laboratory project for third edition.

11. Stability and Storage Conditions

Dextrose has good stability under dry storage conditions. Aqueous solutions may be sterilized by autoclaving. However, excessive heating can cause a reduction in pH and caramelization of solutions.⁽⁴⁻⁷⁾

The bulk material should be stored in a well-closed container in a cool, dry, place.




Fig. 2: Sorption-desorption isotherm for anhydrous dextrose granules.^(b)

◆ : sorption
 ■ : desorption

12. Incompatibilities

Dextrose solutions are incompatible with a number of drugs such as: cyanocobalamin; kanamycin sulfate; novobiocin sodium, and warfarin sodium.⁽⁸⁾ Erythromycin gluceptate is unstable in dextrose solutions at a pH less than 5.05.⁽⁹⁾ Decomposition of B-complex vitamins may occur if they are warmed with dextrose.

In the aldehyde form, dextrose can react with amines, amides, amino acids, peptides, and proteins. Brown coloration and decomposition occurs with strong alkali.

Dextrose may cause browning of tablets containing amines.

13. Method of Manufacture

Dextrose, a monosaccharide sugar, occurs widely in plants and is manufactured on a large scale by the acid and enzymatic hydrolysis of starch, usually maize (corn) starch. Below 50°C α -D-dextrose monohydrate is the stable crystalline form produced, above 50°C the anhydrous form is obtained and at still higher temperatures β -D-dextrose is formed which has a melting point of 148-155°C.

14. Safety

Dextrose is rapidly absorbed from the gastrointestinal tract. It is metabolized to carbon dioxide and water with the release of energy.

Concentrated dextrose solutions given by mouth may cause nausea and vomiting. Dextrose solutions greater than 5% w/v concentration are hyperosmotic and are liable to cause local vein irritation following intravenous administration. Thrombophlebitis has been observed following the intravenous infusion of iso-osmotic dextrose solution with low pH, probably due to the presence of degradation products formed by over-heating during sterilization. The incidence of phlebitis may be reduced by adding sufficient sodium bicarbonate to raise the pH of the infusion above pH 7.

LD₅₀ (mouse, IP): 18 g/kg⁽¹⁰⁾

LD₅₀ (mouse, IV): 9 g/kg

LD₅₀ (rat, oral): 25.8 g/kg

15. Handling Precautions

Observe normal precautions appropriate to the circumstances and quantity of material handled. Eye protection and gloves are recommended. Dust generation should be minimized to reduce the risk of explosion.

16. Regulatory Status

Included in the FDA Inactive Ingredients Guide (capsules, inhalations, IM, IV and SC injections, tablets, oral solutions, and syrups). Included in nonparenteral and parenteral medicines licensed in the UK.

17. Pharmacopeias

China, Eur, Int, and US.

Some pharmacopeias include separate monographs for dextrose anhydrous and/or dextrose monohydrate while others permit the anhydrous and/or monohydrate under a single monograph. The JP, for example, only includes anhydrous dextrose. The USP also includes a monograph for dextrose excipient; this material is dextrose monohydrate not intended for parenteral use, and with a specific optical rotation of +52.5° to +53.5°.

18. Related Substances

Dextrates; dextrin; dextrose anhydrous; fructose; glucose liquid; sucrose.

Dextrose anhydrous: C₆H₁₂O₆

Molecular weight: 180.16

CAS number: [50-99-7]

Synonyms: anhydrous D-(+)-glucopyranose; anhydrous glucose; anhydrous dextrose; dextrosium anhydricum.

Appearance: white, odorless, crystalline powder with a sweet taste.

Pharmacopeias: Eur, Int, Jpn, Pol, and US.

Acidity/alkalinity: pH = 5.9 (10% w/v aqueous solution)

Density (bulk): 1.3-1.4 g/cm³

Density (tapped): 1.1-1.2 g/cm³

Hygroscopicity: see Section 10.

Melting point: 146°C

Osmolarity: a 5.05% w/v aqueous solution is iso-osmotic with serum. See also Section 10.

Refractive index: n_D²⁰ = 1.3479 (10% w/v aqueous solution)

Solubility:

| Solvent | Solubility at 20°C Unless otherwise stated |
|---------------|---|
| Ethanol (95%) | Sparingly soluble |
| Ether | Sparingly soluble |
| Methanol | 1 in 120 |
| Water | 1 in 1.1 at 25°C 1 in 0.8 at 30°C 1 in 0.41 at 50°C 1 in 0.28 at 70°C 1 in 0.18 at 90°C |

Specific gravity:

| Concentration of aqueous dextrose solution (% w/v) | Specific gravity at 17.5°C |
|---|-------------------------------|
| 5 | 1.019 |
| 10 | 1.038 |
| 20 | 1.076 |
| 30 | 1.113 |
| 40 | 1.149 |

Specific surface area: 0.22-0.29 m²/g.^(a)

^(a) Results of laboratory project for third edition.

19. Comments

The way in which the strengths of dextrose solutions are expressed varies from country to country. The USP requires strengths to be expressed in terms of dextrose monohydrate while the BP requires strengths to be expressed in terms of anhydrous dextrose. Approximately 1.1 g of dextrose monohydrate is equivalent to 1 g of anhydrous dextrose.

20. Specific References

- DuVall RN, Koshy KT, Dashiell RE. Comparative evaluation of dextrose and spray-dried lactose in direct compression systems. *J Pharm Sci* 1965; 54: 1196-1200.
- Henderson NL, Bruno AJ. Lactose USP (beadlets) and dextrose (PAF 2011): two new agents for direct compression. *J Pharm Sci* 1970; 59: 1336-1340.
- Armstrong NA, Patel A, Jones TM. The compressional properties of dextrose monohydrate and anhydrous dextrose of varying water contents. In: Rubinstein MH, editor. *Pharmaceutical Technology: Tableting Technology*, volume 1. Chichester, Ellis Horwood, 1987; 127-138.
- Wing WT. An examination of the decomposition of dextrose solution during sterilisation. *J Pharm Pharmacol* 1960; 12: 191T-196T.
- Murty BSR, Kapoor JN, Smith FX. Levels of 5-hydroxymethylfurfural in dextrose injection. *Am J Hosp Pharm* 1977; 34: 205-206.
- Sturgeon RJ, Athanikar NK, Harbison HA, Henry RS, Jurgens RW, Welco AD. Degradation of dextrose during heating under simulated sterilization. *J Parenter Drug Assoc* 1980; 34: 175-182.
- Durham DG, Hung CT, Taylor RB. Identification of some acids produced during autoclaving of D-glucose solutions using HPLC. *Int J Pharmaceutics* 1982; 12: 31-40.
- Patel JA, Phillips GL. A guide to physical compatibility of intravenous drug admixtures. *Am J Hosp Pharm* 1966; 23: 409-411.
- Edward M. pH - an important factor in the compatibility of additives in intravenous therapy. *Am J Hosp Pharm* 1967; 24: 440-449.
- Sweet DV, editor. Registry of Toxic Effects of Chemical Substances. Cincinnati, US Department of Health, 1987

21. General References

-

22. Authors

A Day.

Edetic Acid

1. Nonproprietary Names

BP: Edetic acid
USP: Edetic acid

2. Synonyms

Edathamil; EDTA; ethylenediaminetetraacetic acid; (ethylenedinitrilo)tetraacetic acid; *Questric acid 5286*; *Sequestrene AA*; tetracemic acid; *Versene Acid*.

3. Chemical Name and CAS Registry Number


N,N-1,2-Ethanediybis[*N*-(carboxymethyl)glycine] [60-00-4]

4. Empirical Formula Molecular Weight

$C_{10}H_{16}N_2O_8$

292.24

5. Structural Formula



6. Functional Category

Chelating agent.

7. Applications in Pharmaceutical Formulation or Technology

Edetic acid and edetate salts are used in pharmaceutical formulations, cosmetics, and foods as chelating agents; that is, they form stable water-soluble complexes (chelates) with alkaline earth and heavy metal ions. The chelated form has few of the properties of the free ion, and for this reason chelating agents are often described as 'removing' ions from solution; this process is also called sequestering. The stability of the metal-edetate complex depends on the metal ion involved and also on the pH. The calcium chelate is relatively weak and will preferentially chelate heavy metals, such as iron, copper, and lead, with the release of calcium ions. For this reason, edetate calcium disodium is used therapeutically in cases of lead poisoning, *see also* Section 19.

Edetic acid and edetates are primarily used as antioxidant synergists by sequestering trace amounts of metal ions, particularly copper, iron, and manganese, which might otherwise catalyze autoxidation reactions. Edetic acid and edetates may be used alone or in combination with true antioxidants, the usual concentration employed being in the range 0.005-0.1% w/v. Edetates have been used to stabilize: ascorbic acid; corticosteroids; epinephrine; folic acid; formaldehyde; gums and resins; hyaluronidase; hydrogen peroxide; oxytetracycline; penicillin; salicylic acid, and unsaturated fatty acids. Essential oils may be washed with a 2% w/v solution of edetate to remove trace metal impurities.

Edetic acid and edetates possess some antimicrobial activity but are most frequently used in combination with other antimicrobial preservatives due to their synergistic effects. Many solutions used for the cleaning, storage, and wetting of contact lenses thus contain disodium edetate. Typically, edetic acid and edetates are used in concentrations of 0.01-0.1% w/v as antimicrobial preservative synergists, *see* Section 10.

Edetic acid and disodium edetate may also be used as water softeners since they will chelate the calcium and magnesium ions present in hard water; edetate calcium disodium is not effective. Many cosmetic and toiletry products, e.g., soaps, contain edetic acid as a water softener.

Disodium edetate is also used as an anticoagulant since it will chelate calcium and prevent the coagulation of blood *in vitro*. Concentrations of 0.1% w/v are used in small volumes for hematological testing and 0.3% w/v in transfusions.

8. Description

Edetic acid occurs as a white crystalline powder.

9. Pharmacopeial Specifications

| Test | BP | USP |
|------------------------|-------------|-------------|
| Identification | + | + |
| Appearance of solution | + | — |
| Residue on ignition | — | ≤ 0.2% |
| Sulfated ash | ≤ 0.2% | — |
| Heavy metals | ≤ 20 ppm | ≤ 0.003% |
| Nitrilotriacetic acid | ≤ 200 ppm | ≤ 0.3% |
| Iron | ≤ 80 ppm | ≤ 0.005% |
| Chloride | ≤ 200 ppm | — |
| Loss on drying | ≤ 0.1% | — |
| Assay | 98.0-101.0% | 98.0-100.5% |

10. Typical Properties

Acidity/alkalinity:

pH = 2.2 for a 0.2% w/v aqueous solution.

Antimicrobial activity: edetic acid has some antimicrobial activity against Gram-negative microorganisms, *Pseudomonas aeruginosa*, some yeasts, and fungi, although this activity is insufficient for edetic acid to be used effectively as an antimicrobial preservative on its own.^(1,2) However, when used with other antimicrobial preservatives edetic acid demonstrates a marked synergistic effect in its antimicrobial activity. Edetic acid and edetates are therefore frequently used in combination with such preservatives as: benzalkonium chloride; bronopol; cetrinide; imidurea; parabens; and phenols, especially chloroxylenol. Typically, edetic acid is used at a concentration of 0.1-0.15% w/v. In the presence of some divalent metal ions, such as Ca^{2+} or Mg^{2+} , the synergistic effect may be reduced or lost altogether. The addition of disodium edetate to phenylmercuric nitrate⁽³⁾ and thimerosal^(3,4) has also been reported to reduce the antimicrobial efficacy of the preservative. Edetic acid and iodine form a colorless addition compound which is bactericidal.

Dissociation constant:

$pK_{a1} = 2.00$;

$pK_{a2} = 2.67$;

$pK_{a3} = 6.16$;

$pK_{a4} = 10.26$.

Melting point: melts above 220°C, with decomposition.

Solubility: soluble in solutions of alkali hydroxides; soluble 1 in 500 of water.

11. Stability and Storage Conditions

Although edetic acid is fairly stable in the solid state, edetate salts are more stable than the free acid, which decarboxylates if heated above 150°C. Disodium edetate dihydrate loses water of crystallization when heated to 120°C. Edetate calcium disodium is slightly hygroscopic and should be protected from moisture.

Aqueous solutions of edetic acid or edetate salts may be sterilized by autoclaving, and should be stored in an alkali-free container.

Edetic acid and edetates should be stored in well-closed containers in a cool, dry, place.

12. Incompatibilities

Edetic acid and edetates are incompatible with strong oxidizing agents, strong bases, and polyvalent metal ions such as copper, nickel, and copper alloy.

Edetic acid and disodium edetate behave as weak acids, displacing carbon dioxide from carbonates and reacting with metals to form hydrogen.

Other incompatibilities include the inactivation of certain types of insulin due to the chelation of zinc, and the chelation of trace metals in TPN solutions following the addition of TPN additives stabilized with disodium edetate. Calcium disodium edetate has also been reported to be incompatible with amphotericin and with hydralazine hydrochloride in infusion fluids.

13. Method of Manufacture

Edetic acid may be prepared by the condensation of ethylenediamine with sodium monochloroacetate in the presence of sodium carbonate. An aqueous solution of the reactants is heated to about 90°C for 10 hours, then cooled, and hydrochloric acid added to precipitate the edetic acid.

Edetic acid may also be prepared by the reaction of ethylenediamine with hydrogen cyanide and formaldehyde with subsequent hydrolysis of the tetranitrile, or under alkaline conditions with continuous extraction of ammonia.

See Section 18 for information on the preparation of edetate salts.

14. Safety

Edetic acid and edetates are widely used in topical, oral, and parenteral pharmaceutical formulations. They are also extensively used in cosmetics and food products.

Edetic acid is generally regarded as an essentially nontoxic and nonirritant material although it has been associated with dose-related bronchoconstriction when used as a preservative in nebulizer solutions. It has therefore been recommended that nebulizer solutions for bronchodilation should not contain edetic acid.⁽⁵⁾

Edetates, particularly disodium edetate and edetate calcium disodium, are used in a greater number and variety of pharmaceutical formulations than the free acid. Both disodium edetate and edetate calcium disodium are poorly absorbed from the gastrointestinal tract and are associated with few adverse effects when used as excipients in pharmaceutical formulations.

Disodium edetate, trisodium edetate, and edetic acid readily chelate calcium and can, in large doses, cause calcium depletion (hypocalcemia) if used over an extended period or if administered

too rapidly by intravenous infusion. If used in preparations for the mouth, they can also leach calcium from the teeth. In contrast, edetate calcium disodium does not chelate calcium.

Edetate calcium disodium is nephrotoxic and should be used with caution in patients with renal impairment. Disodium edetate should similarly be used with caution in patients with renal impairment, tuberculosis, and impaired cardiac function.

The WHO has set an estimated acceptable daily intake for disodium edetate in foodstuffs at up to 2.5 mg/kg body-weight.⁽⁶⁾

See also Section 19.

LD₅₀ (mouse, IP): 0.25 g/kg⁽⁷⁾

LD₅₀ (mouse, oral): 0.03 g/kg

LD₅₀ (rat, IP): 0.397 g/kg

15. Handling Precautions

Observe normal precautions appropriate to the circumstances and quantity of material handled. Edetic acid and edetates are mildly irritant to the skin, eyes, and mucous membranes. Ingestion, inhalation, and contact with the skin and eyes should therefore be avoided. Eye protection, gloves, and a dust mask are recommended.

16. Regulatory Status

Included in the FDA Inactive Ingredients Guide (otic, rectal, and topical preparations). Included in nonparenteral medicines licensed in the UK.

See also Section 18.

17. Pharmacopeias

Br, Ger, and US.

18. Related Substances

Dipotassium edetate: C₁₀H₁₄K₂N₂O₈

Molecular weight: 368.46

CAS number: [2001-94-7]

Synonyms: dipotassium edathamil; dipotassium ethylenediaminetetraacetate; edathamil dipotassium; edetate dipotassium; edetic acid dipotassium salt; EDTA dipotassium; *N,N'*-1,2-ethanediybis[*N*-(carboxymethyl)glycine] dipotassium salt; ethylenebis(iminodiacetic acid) dipotassium salt; ethylenediaminetetraacetic acid dipotassium salt; (ethylenedinitrilo)tetraacetic acid dipotassium salt; tetracemate dipotassium.

Appearance: white crystalline powder.

Disodium edetate: C₁₀H₁₄N₂Na₂O₈

Molecular weight: 336.21

CAS number:

[139-33-3] for the anhydrous material;

[6381-92-6] for the dihydrate.

Synonyms: disodium edathamil; disodium ethylenediaminetetraacetate; edathamil disodium; edetate disodium; edetic acid disodium salt; EDTA disodium; *N,N'*-1,2-ethanediybis[*N*-(carboxymethyl)glycine] disodium salt; ethylenebis(iminodiacetic acid) disodium salt; ethylenediaminetetraacetic acid disodium salt; (ethylenedinitrilo)tetraacetic acid disodium salt; *Questal Di*; *Sequestrene NA2*; tetracemate disodium; *Versene disodium*.

Appearance: odorless white crystalline powder with a slightly acid taste.

Pharmacopeias: Eur, Int, Jpn, Pol, and US.

Acidity/alkalinity: pH = 4.3-4.7 for a 1% w/v solution in carbon dioxide free water.

Freezing point depression:
0.14°C (1% w/v aqueous solution)

Melting point:
decomposition at 252°C for the dihydrate.

Refractive index:
1.335 for a 1% w/v aqueous solution.

Solubility: practically insoluble in chloroform and ether; slightly soluble in ethanol (95%); soluble 1 in 11 of water.

Specific gravity:
1.004 for a 1% w/v aqueous solution.

Viscosity (kinematic): 1.03 mm²/s (1 cSt) for a 1% w/v aqueous solution.

Method of manufacture: disodium edetate may be prepared by the reaction of edetic acid and sodium hydroxide.

Safety: see also Section 14.

LD₅₀ (mouse, IP): 0.26 g/kg⁽⁷⁾

LD₅₀ (mouse, IV): 0.056 g/kg

LD₅₀ (mouse, oral): 2.05 g/kg

LD₅₀ (rabbit, IV): 0.047 g/kg

LD₅₀ (rabbit, oral): 2.3 g/kg

LD₅₀ (rat, oral): 2 g/kg

LD₅₀ (rat, SC): 3.735 g/kg

Regulatory status: GRAS listed. Included in the FDA Inactive Ingredients Guide (inhalations, injections, ophthalmic preparations, oral capsules, solutions, suspensions, syrups and tablets, rectal, topical, and vaginal preparations). Included in nonparenteral and parenteral medicines licensed in the UK.

Comments: in pharmaceutical formulations disodium edetate is used as a chelating agent typically at concentrations between 0.005-0.1% w/v.

Edetate calcium disodium: C₁₀H₁₂CaN₂Na₂O₈

Molecular weight: 374.28

CAS number:

[62-33-9] for the anhydrous material;

[23411-34-9] for the dihydrate.

Synonyms: 385; calcium disodium edetate; calcium disodium ethylenediaminetetraacetate; calcium disodium (ethylenedinitrilo)tetraacetate; edathamil calcium disodium; edetic acid calcium disodium salt; [[N',N'-1,2-ethanediy]bis[N-(carboxymethyl)glycinato]](4-)-N,N',O,O',O^N,-O^N]calcate(2-)-disodium; EDTA calcium; ethylenediaminetetraacetic acid calcium disodium chelate; [(ethylenedinitrilo)tetraacetato]calcate(2-)-disodium; sodium calcium edetate; *Versene CA*.

Appearance: white or creamy-white colored, slightly hygroscopic, crystalline powder or granules; odorless, or with a slight odor; tasteless, or with a faint saline taste.

Pharmacopeias: Eur, Pol, and US. Some pharmacopeias specify that edetate calcium disodium is the dihydrate, others that it is the anhydrous material. The USP specifies that edetate calcium disodium is a mixture of the dihydrate and trihydrate but that the dihydrate predominates.

Acidity/alkalinity:

pH = 4-5 for a 1% w/v aqueous solution.

Density (bulk): 0.69 g/cm³

Solubility: practically insoluble in chloroform, ether, and other organic solvents; very slightly soluble in ethanol (95%); soluble 1 in 2 of water.

Method of manufacture: edetate calcium disodium may be prepared by the addition of calcium carbonate to a solution of disodium edetate.

Safety: see also Section 14.

LD₅₀ (dog, oral): 12 g/kg⁽⁷⁾

LD₅₀ (mouse, IP): 4.5 g/kg

LD₅₀ (mouse, oral): 10 g/kg

LD₅₀ (rabbit, IP): 6 g/kg

LD₅₀ (rabbit, oral): 7 g/kg

LD₅₀ (rat, IP): 3.85 g/kg

LD₅₀ (rat, IV): 3.0 g/kg

LD₅₀ (rat, oral): 10 g/kg

Regulatory status: GRAS listed. Accepted for use as a food additive in the UK. Included in the FDA Inactive Ingredients Guide (injections, oral capsules, solutions, suspensions, syrups, and tablets).

Comments: used in pharmaceutical formulations as a chelating agent in concentrations between 0.01-0.1% w/v. Usually edetate calcium disodium is used in pharmaceutical formulations in preference to disodium edetate or sodium edetate to prevent calcium depletion occurring in the body. In food products, edetate calcium disodium may also be used in flavors and as a color retention agent. Edetate calcium disodium occurs as the dihydrate, trihydrate, and anhydrous material.

Sodium edetate: C₁₀H₁₂N₂Na₄O₈

Molecular weight: 380.20

CAS number: [64-02-8]

Synonyms: edetate sodium; edetic acid tetrasodium salt; EDTA tetrasodium; N,N'-1,2-ethanediy]bis[N-(carboxymethyl)glycine] tetrasodium salt; ethylenebis(iminodiacetic acid) tetrasodium salt; ethylenediaminetetraacetic acid tetrasodium salt; (ethylenedinitrilo)tetraacetic acid tetrasodium salt; *Sequestrene NA4*; tetracemate tetrasodium; tetracemin; tetrasodium edetate; tetrasodium ethylenebis(iminodiacetate); tetrasodium ethylenediaminetetraacetate; *Versene*.

Appearance: white crystalline powder.

Acidity/alkalinity:

pH = 11.3 for a 1% w/v aqueous solution.

Melting point: > 300°C

Solubility: soluble 1 in 1 of water.

Safety: see also Section 14.

LD₅₀ (mouse, IP): 0.33 g/kg⁽⁷⁾

Regulatory status: included in the FDA Inactive Ingredients Guide (inhalations, injections, ophthalmic preparations, oral capsules and tablets, and topical preparations).

Comments: sodium edetate reacts with most divalent and trivalent metallic ions to form soluble metal chelates and is used in pharmaceutical formulations in concentrations between 0.01-0.1% w/v.

Trisodium edetate: C₁₀H₁₃N₂Na₃O₈

Molecular weight: 358.20

CAS number: [150-38-9]

Synonyms: edetate trisodium; edetic acid trisodium salt; EDTA trisodium; N,N'-1,2-ethanediy]bis[N-(carboxymethyl)glycine] trisodium salt; ethylenediaminetetraacetic acid trisodium salt; (ethylenedinitrilo)tetraacetic acid trisodium salt; *Sequestrene NA3*; trisodium ethylenediaminetetraacetate; *Versene-9*.

Appearance: white crystalline powder.

Acidity/alkalinity:

pH = 9.3 for a 1% w/v aqueous solution.

Melting point: > 300°C

Method of manufacture: trisodium edetate may be prepared by adding a solution of sodium hydroxide to disodium edetate.

Safety: see also Section 14.

LD₅₀ (mouse, IP): 0.3 g/kg⁽⁷⁾

LD₅₀ (mouse, oral): 2.15 g/kg

LD₅₀ (rat, oral): 2.15 g/kg

Regulatory status: included in the FDA Inactive Ingredients Guide (topical preparations).

Comments: more soluble in water than either the disodium salt or the free acid. Trisodium edetate also occurs as the monohydrate and is used in pharmaceutical formulations as a chelating agent.

Other salts of edetic acid which are commercially available include diammonium, dimagnesium, dipotassium, ferric sodium, and magnesium disodium edetates.

19. Comments

Therapeutically, a dose of 50 mg/kg body-weight of disodium edetate, as a slow infusion over a 24-hour period, with a maximum daily dose of 3 g, has been used as a treatment for hypercalcemia. For the treatment of lead poisoning, a dose of 60-80 mg/kg of edetate calcium disodium, as a slow infusion in two daily doses, for 5 days, has been used.

20. Specific References

1. Richards RME, Cavill RH. Electron microscope study of effect of benzalkonium chloride and edetate disodium on cell envelope of *Pseudomonas aeruginosa*. *J Pharm Sci* 1976; 65: 76-80.
2. Whalley G. Preservative properties of EDTA. *Mfg Chem* 1991; 62(9): 22-23.

3. Richards RME, Reary JME. Changes in antibacterial activity of thiomersal and PMN on autoclaving with certain adjuvants. *J Pharm Pharmacol* 1972; 24(Suppl): 84P-89P.
4. Morton DJ. EDTA reduces antimicrobial efficacy of thiomersal. *Int J Pharmaceutics* 1985; 23: 357-358.
5. Beasley CRW, Rafferty P, Holgate ST. Bronchoconstrictor properties of preservatives in ipratropium bromide (Atrovent) nebuliser solution. *Br Med J* 1987; 294: 1197-1198.
6. FAO/WHO. Toxicological evaluation of certain food additives with a review of general principles and of specifications. Seventeenth report of the joint FAO/WHO expert committee on food additives. *Tech Rep Ser Wld Hlth Org* 1974; No. 539.
7. Sweet DV, editor. Registry of Toxic Effects of Chemical Substances. Cincinnati, US Department of Health, 1987

21. General References

- Chalmers L. The uses of EDTA and other chelates in industry. *Mfg Chem* 1978; 49(3): 79-80, 83.
- Hart JR. Chelating agents in cosmetic and toiletry products. *Cosmet Toilet* 1978; 93(12): 28-30.
- Hart JR. EDTA-type chelating agents in personal care products. *Cosmet Toilet* 1983; 98(4): 54-58.
- Lachman L. Antioxidants and chelating agents as stabilizers in liquid dosage forms. *Drug Cosmet Ind* 1968; 102(2): 43-45, 146-149.

22. Authors

PJ Weller.

Glycerin

1. Nonproprietary Names

BP: Glycerol
JP: Concentrated Glycerin
PhEur: Glycerolum
USP: Glycerin

2. Synonyms

Croderol; E422; glycerine; *Glycon G-100*; *Kemstrene*; *Pricerine*; 1,2,3-propanetriol; trihydroxypropane glycerol.


3. Chemical Name and CAS Registry Number

Propane-1,2,3-triol [56-81-5]

4. Empirical Formula Molecular Weight

C₃H₈O₃ 92.09

5. Structural Formula



6. Functional Category

Antimicrobial preservative; emollient; humectant; plasticizer; solvent; sweetening agent; tonicity agent.

7. Applications in Pharmaceutical Formulation or Technology

Glycerin is used in a wide variety of pharmaceutical formulations including oral, otic, ophthalmic, topical, and parenteral preparations. It is also used in cosmetics and as a food additive.

In topical pharmaceutical formulations and cosmetics, glycerin is used primarily for its humectant and emollient properties. In parenteral formulations glycerin is mainly used as a solvent.⁽¹⁾ In oral solutions glycerin is used as a solvent, sweetening agent, antimicrobial preservative, and viscosity-increasing agent. Glycerin is also used as a plasticizer of gelatin in the production of soft-gelatin capsules and gelatin suppositories. Glycerin is additionally employed as a therapeutic agent in a variety of clinical applications.

| Use | Concentration (%) |
|---------------------------------------|-------------------|
| Antimicrobial preservative | > 20 |
| Emollient | Up to 30 |
| Humectant | Up to 30 |
| Ophthalmic formulations | 0.5-3.0 |
| Plasticizer in tablet film coating | Variable |
| Solvent for parenteral formulations | Up to 50 |
| Sweetening agent in alcoholic elixirs | Up to 20 |

8. Description

Glycerin is a clear, colorless, odorless, viscous, hygroscopic liquid; it has a sweet taste, approximately 0.6 times as sweet as sucrose.

9. Pharmacopeial Specifications

| Test | JP | PhEur | USP |
|---|-------------|-------------|-----------|
| Identification | + | + | + |
| Characters | + | — | + |
| Specific gravity | 1.221-1.230 | — | ≥ 1.249 |
| Color | + | — | + |
| Appearance of solution | — | + | — |
| Acidity or alkalinity | + | — | + |
| Refractive index | 1.449-1.454 | 1.470-1.475 | — |
| Residue on ignition | ≤ 0.01% | — | ≤ 0.01% |
| Sulfated ash | — | ≤ 0.01% | — |
| Chloride | ≤ 0.001% | ≤ 10 ppm | ≤ 0.001% |
| Ammonium | + | — | — |
| Calcium | + | — | — |
| Sulfate | ≤ 0.002% | — | ≤ 0.002% |
| Arsenic | ≤ 2 ppm | — | ≤ 1.5 ppm |
| Heavy metals | ≤ 5 ppm | ≤ 5 ppm | ≤ 5 ppm |
| Chlorinated compounds (as Cl) | — | + | ≤ 0.003% |
| Organic volatile impurities | — | — | + |
| Aldehydes | — | + | — |
| Acrolein, glucose and other reducing substances | + | + | — |
| Fatty acids and esters | + | + | + |
| Readily carbonizable substances | + | — | — |
| Sugars | — | + | — |
| Water | — | ≤ 2.0% | ≤ 5.0% |
| Assay | 84%-87% | 98-101% | 99-101% |

10. Typical Properties

Boiling point: 290°C (with decomposition)

Density:

1.2656 g/cm³ at 15°C;

1.2636 g/cm³ at 20°C;

1.2620 g/cm³ at 25°C.

Flash point: 176°C (open cup)

Freezing point:

| Concentration of aqueous glycerin solution (% w/w) | Freezing point (°C) |
|--|---------------------|
| 10 | -1.6 |
| 20 | -4.8 |
| 30 | -9.5 |
| 40 | -15.4 |
| 50 | -23 |
| 60 | -34.7 |
| 66.7 | -46.5 |
| 80 | -20.3 |
| 90 | -1.6 |

Hygroscopicity: hygroscopic.

Melting point: 17.8°C

Osmolarity: a 2.6% v/v aqueous solution is iso-osmotic with serum.

Refractive index:

$n_D^{15} = 1.4758;$

$n_D^{20} = 1.4746;$

$n_D^{25} = 1.4730.$

Solubility:

| Solvent | Solubility at 20°C |
|---------------|-----------------------|
| Acetone | Slightly soluble |
| Benzene | Practically insoluble |
| Chloroform | Practically insoluble |
| Ethanol (95%) | Soluble |
| Ether | 1 in 500 |
| Ethyl acetate | 1 in 11 |
| Methanol | Soluble |
| Oils | Practically insoluble |
| Water | Soluble |

Specific gravity:

| Concentration of aqueous glycerin solution (% w/w) | Specific gravity at 20°C |
|--|--------------------------|
| 10 | 1.024 |
| 20 | 1.049 |
| 30 | 1.075 |
| 40 | 1.101 |
| 50 | 1.128 |
| 60 | 1.156 |

Surface tension:

63.4 mN/m (63.4 dynes/cm) at 20°C.

Vapor density (relative): 3.17 (air = 1)**Viscosity (dynamic):**

| Concentration of aqueous glycerin solution (% w/w) | Viscosity at 20°C (mPa s) |
|--|---------------------------|
| 5 | 1.143 |
| 10 | 1.311 |
| 25 | 2.095 |
| 50 | 6.05 |
| 60 | 10.96 |
| 70 | 22.94 |
| 83 | 111 |

11. Stability and Storage Conditions

Glycerin is hygroscopic. Pure glycerin is not prone to oxidation by the atmosphere under ordinary storage conditions, but decomposes on heating, with the evolution of toxic acrolein. Mixtures of glycerin with water, ethanol, and propylene glycol are chemically stable.

Glycerin may crystallize if stored at low temperatures; the crystals do not melt until raised to 20°C.

Glycerin should be stored in an airtight container, in a cool, dry, place.

12. Incompatibilities

Glycerin may explode if mixed with strong oxidizing agents such as chromium trioxide, potassium chlorate, or potassium permanganate. In dilute solution, the reaction proceeds at a

slower rate with several oxidation products being formed. Black discoloration of glycerin occurs in the presence of light, on contact with zinc oxide or basic bismuth nitrate.

An iron contaminant in glycerin is responsible for the darkening in color of mixtures containing phenols, salicylates, and tannin.

Glycerin forms a boric acid complex, glyceroboric acid, which is a stronger acid than boric acid.

13. Method of Manufacture

Glycerin is mainly obtained from oils and fats as a by-product in the manufacture of soaps and fatty acids. It may also be obtained from natural sources by fermentation of, for example, sugar beet molasses in the presence of large quantities of sodium sulfite. Synthetically, glycerin may be prepared by the chlorination and saponification of propylene.

14. Safety

Glycerin occurs naturally in animal and vegetable fats and oils that are consumed as part of a normal diet. Glycerin is readily absorbed from the intestine and is either metabolized to carbon dioxide and glycogen or is used in the synthesis of body fats.

Glycerin is used in a wide variety of pharmaceutical formulations including oral, ophthalmic, parenteral, and topical preparations. Adverse effects are mainly due to the dehydrating properties of glycerin.

Oral doses are demulcent and mildly laxative in action. Large doses may produce headache, thirst, nausea, and hyperglycemia. The therapeutic parenteral administration of very large glycerin doses, 70-80 g over 30-60 minutes in adults to reduce cranial pressure, may induce hemolysis, hemoglobinuria, and renal failure.⁽²⁾ Slower administration has no deleterious effects.⁽³⁾

Glycerin may also be used orally in doses of 1.0-1.5 g/kg body-weight to reduce intraocular pressure.

When used as an excipient or food additive, glycerin is not usually associated with any adverse effects and is generally regarded as a nontoxic and nonirritant material.

LD₅₀ (guinea pig, oral): 7.75 g/kg⁽⁴⁾

LD₅₀ (mouse, IP): 8.98 g/kg

LD₅₀ (mouse, IV): 6.2 g/kg

LD₅₀ (mouse, oral): 4.1 g/kg

LD₅₀ (mouse, SC): 0.09 g/kg

LD₅₀ (rat, IP): 8.3 g/kg

LD₅₀ (rat, IV): 5.6 g/kg

LD₅₀ (rat, oral): 12.6 g/kg

LD₅₀ (rat, SC): 0.1 g/kg

15. Handling Precautions

Observe normal precautions appropriate to the circumstances and quantity of material handled. Eye protection and gloves are recommended. In the UK, the recommended long-term (8-hour TWA) exposure limit for glycerin mist is 10 mg/m³.⁽⁵⁾ Glycerin is combustible and may react explosively with strong oxidizing agents, see Section 12.

16. Regulatory Status

GRAS listed. Accepted as a food additive in Europe. Included in the FDA Inactive Ingredients Guide (inhalations, injections, nasal, ophthalmic, oral capsules, solutions, suspensions and

tablets, otic, rectal, topical, transdermal, and vaginal preparations). Included in nonparenteral and parenteral medicines licensed in the UK.

17. Pharmacopeias

China, Eur, Int, Jpn, and US.

Eur and Int also include glycerin (85%); Pol includes glycerin (86%).

18. Related Substances

—

19. Comments

—

20. Specific References

1. Spiegel AJ, Noseworthy MM. Use of nonaqueous solvents in parenteral products. *J Pharm Sci* 1963; 52: 917-927.

2. Hågnevik K, Gordon E, Lins LE, Wilhelmsson S, Forster D. Glycerol-induced haemolysis with haemoglobinuria and acute renal failure. *Lancet* 1974; i: 75-77.
3. Welch KMA, Meyer JS, Okamoto S, Mathew NT, Rivera VM, Bond J. Glycerol-induced haemolysis [letter]. *Lancet* 1974; i: 416-417.
4. Sweet DV, editor. Registry of Toxic Effects of Chemical Substances. Cincinnati, US Department of Health, 1987
5. Health and Safety Executive. EH40/98: Occupational exposure limits 1998. Sudbury, Health and Safety Executive, 1998.

21. General References

- Grissom CB, Chagovetz AM, Wang Z. Use of viscosigens to stabilize vitamin B₁₂ solutions against photolysis. *J Pharm Sci* 1993; 82: 641-643.
- Jungermann E, Sonntag NOV, editors. *Glycerine: A Key Cosmetic Ingredient*. New York, Marcel Dekker Inc, 1991.
- Smolinske SC. *Handbook of Food, Drug, and Cosmetic Excipients*. Boca Raton, FL, CRC Press Inc, 1992; 199-204.
- Staples R, Misher A, Wardell J. Gastrointestinal irritant effect of glycerin as compared with sorbitol and propylene glycol in rats and dogs. *J Pharm Sci* 1967; 56: 398-400.

22. Authors

JC Price.

Hydroxypropyl Methylcellulose

1. Nonproprietary Names

BP: Hypromellose
 JP: Hydroxypropylmethylcellulose
 PhEur: Methylhydroxypropylcellulosum
 USP: Hydroxypropyl methylcellulose

2. Synonyms

Benecel MHPC; Cellulose, hydroxypropyl methyl ether; E464; HPMC; *Methocel*; methylcellulose propylene glycol ether; methyl hydroxypropylcellulose; *Metolose*; *Pharmacoat*.


3. Chemical Name and CAS Registry Number

Cellulose, 2-Hydroxypropyl methyl ether [9004-65-3]

4. Empirical Formula Molecular Weight

The PhEur describes hydroxypropyl methylcellulose as a partly *O*-methylated and *O*-(2-hydroxypropylated) cellulose. It is available in several grades which vary in viscosity and extent of substitution. Grades may be distinguished by appending a number indicative of the apparent viscosity, in mPa s, of a 2% w/w aqueous solution at 20°C. Hydroxypropyl methylcellulose defined in the USP specifies the substitution type by appending a four digit number to the nonproprietary name, e.g., hydroxypropyl methylcellulose 1828. The first two digits refer to the approximate percentage content of the methoxy group (OCH₃). The second two digits refer to the approximate percentage content of the hydroxypropoxy group (OCH₂CHOHCH₃), calculated on a dried basis. Molecular weight is approximately 10 000-1 500 000.

5. Structural Formula



Where R is H, CH₃, or [CH₃CH(OH)CH₂].

6. Functional Category

Coating agent; film-former; rate-controlling polymer for sustained release; stabilizing agent; suspending agent; tablet binder; viscosity-increasing agent.

7. Applications in Pharmaceutical Formulation or Technology

Hydroxypropyl methylcellulose is widely used in oral and topical pharmaceutical formulations.

In oral products, hydroxypropyl methylcellulose is primarily used as a tablet binder,⁽¹⁾ in film-coating,⁽²⁻⁷⁾ and as an extended-release tablet matrix.⁽⁸⁻¹²⁾ Concentrations of between 2-5% w/w may be used as a binder in either wet- or dry-granulation processes. High viscosity grades may be used to retard the release of drugs from a matrix at levels 10-80% w/w in tablets and capsules.

Depending upon the viscosity grade, concentrations between 2-20% w/w are used as film-forming solutions to film-coat tablets. Lower viscosity grades are used in aqueous film-coating solutions while higher viscosity grades are used with organic solvents.

Hydroxypropyl methylcellulose is also used as a suspending and thickening agent in topical formulations, particularly ophthalmic preparations. Compared with methylcellulose, hydroxypropyl methylcellulose produces solutions of greater clarity, with fewer undispersed fibers present, and is therefore preferred in formulations for ophthalmic use. Concentrations of between 0.45-1.0% w/w may be added as a thickening agent to vehicles for eye drops and artificial tear solutions.

Hydroxypropyl methylcellulose is also used as an emulsifier, suspending agent, and stabilizing agent in topical gels and ointments. As a protective colloid, it can prevent droplets and particles from coalescing or agglomerating, thus inhibiting the formation of sediments.

In addition, hydroxypropyl methylcellulose is used in the manufacture of capsules, as an adhesive in plastic bandages and as a wetting agent for hard contact lenses. It is also widely used in cosmetics and food products.

8. Description


Hydroxypropyl methylcellulose is an odorless and tasteless, white or creamy-white colored fibrous or granular powder.

9. Pharmacopeial Specifications

| Test | JP | PhEur | USP |
|----------------------------------|------------|----------|------------|
| Identification | + | + | + |
| Appearance of solution | + | + | — |
| pH (1% w/w solution) | 5.0-8.0 | 5.5-8.0 | — |
| Apparent viscosity | + | + | + |
| Loss on drying | ≤ 5.0% | ≤ 10.0% | ≤ 5.0% |
| Residue on ignition | | | |
| For viscosity grade > 50 mPa s | ≤ 1.5% | — | ≤ 1.5% |
| For viscosity grade ≤ 50 mPa s | ≤ 1.5% | — | ≤ 3.0% |
| For type 1828 of all viscosities | ≤ 1.5% | — | ≤ 5.0% |
| Sulfated ash | — | ≤ 1.0% | — |
| Chlorides | — | ≤ 0.5% | — |
| Heavy metals | — | ≤ 20 ppm | ≤ 0.001% |
| Methoxy content | | | |
| Type 1828 | — | — | 16.5-20.0% |
| Type 2208 | 19.0-24.0% | — | 19.0-24.0% |
| Type 2906 | 27.0-30.0% | — | 27.0-30.0% |
| Type 2910 | 28.0-30.0% | — | 28.0-30.0% |
| Hydroxypropoxy content | | | |
| Type 1828 | — | — | 23.0-32.0% |
| Type 2208 | 4.0-12.0% | — | 4.0-12.0% |
| Type 2906 | 4.0-7.5% | — | 4.0-7.5% |
| Type 2910 | 7.0-12.0% | — | 7.0-12.0% |

SEM: 1

Excipient: Hydroxypropyl methylcellulose
 Manufacturer: Dow Chemical Co
 Lot No.: ME20012N11
 Magnification: 600x
 Voltage: 5kV

**SEM: 2**

Excipient: Hydroxypropyl methylcellulose
 Manufacturer: Dow Chemical Co
 Lot No.: ME20012N11
 Magnification: 60x
 Voltage: 5kV

**10. Typical Properties****Acidity/alkalinity:**

pH = 5.5-8.0 for a 1% w/w aqueous solution.

Ash: 1.5-3.0%, depending upon the grade.

Autoignition temperature: 360°C

Density (bulk): 0.341 g/cm³

Density (tapped): 0.557 g/cm³

Density (true): 1.326 g/cm³

Melting point: browns at 190-200°C; chars at 225-230°C.

Glass transition temperature is 170-180°C.

Moisture content: hydroxypropyl methylcellulose absorbs moisture from the atmosphere, the amount of water absorbed depending upon the initial moisture content and the temperature and relative humidity of the surrounding air. See Fig. 1.

Particle size distribution: See Table I.

Solubility: soluble in cold water, forming a viscous colloidal solution; practically insoluble in chloroform, ethanol (95%), and ether, but soluble in mixtures of ethanol and dichloromethane, mixtures of methanol and dichloromethane, and mixtures of water and alcohol. Certain grades of hydroxypropyl methylcellulose are soluble in aqueous acetone solutions, mixtures of dichloromethane and propan-2-ol, and other organic solvents. See also Section 11.

Specific gravity: 1.26

Viscosity (dynamic): a wide range of viscosity types are commercially available. Aqueous solutions are most commonly prepared although hydroxypropyl methylcellulose may also be dissolved in aqueous alcohols such as ethanol and propan-2-ol provided the alcohol content is less than 50% w/w. Dichloromethane and ethanol mixtures may also be used to prepare viscous hydroxypropyl methylcellulose solutions. Solutions prepared using organic solvents tend to be more viscous; increasing concentration also produces more viscous solutions, see Table II.

To prepare an aqueous solution, it is recommended that hydroxypropyl methylcellulose is dispersed and thoroughly hy-

Table I: Typical particle size distribution for hydroxypropyl methylcellulose.

| | Average particle size (µm) | Cumulative frequency oversize (%) | Weight retained (%) |
|----------------|----------------------------|-----------------------------------|---------------------|
| Lot LC15012N11 | 250 | 5.6 | 5.60 |
| | 200 | 18.8 | 13.20 |
| | 137 | 26.6 | 7.8 |
| | 115 | 35.4 | 8.8 |
| | 90 | 54.4 | 19.0 |
| | 64 | 85.8 | 31.4 |
| Lot LA29012N02 | pan | 100 | 14.0 |
| | 250 | 2.8 | 2.8 |
| | 200 | 15.6 | 12.8 |
| | 137 | 20.6 | 5.0 |
| | 115 | 26.4 | 5.8 |
| | 90 | 42.8 | 16.4 |
| | 64 | 68 | 25.2 |
| | pan | 100 | 33 |

Note: Using an ATM Sonic Softener.

drated in about 20-30% of the required amount of water. The water should be vigorously stirred and heated to 80-90°C then the remaining hydroxypropyl methylcellulose added. Cold water should then be added to produce the required volume.

When a water-miscible organic solvent such as ethanol, glycol, or mixtures of ethanol and dichloromethane is used, the hydroxypropyl methylcellulose should first be dispersed into the organic solvent, at a ratio of 5-8 parts of solvent to 1 part of hydroxypropyl methylcellulose. Cold water is then added to produce the required volume.

11. Stability and Storage Conditions

Hydroxypropyl methylcellulose powder is a stable material although it is hygroscopic after drying.




Fig. 1: Absorption desorption isotherm for hydroxypropyl methylcellulose.

◆ : sorption
 ■ : desorption

Table II: Typical viscosity values for 2% (w/v) aqueous solutions of Methocel (Dow Chemical Co.) Viscosities measured at 20°C.

| Methocel grade | Nominal | Viscosity (mPa s) |
|-------------------------|---------|-------------------|
| K100LVP ^(a) | 100 | 80-120 |
| K4MP ^(a) | 4000 | 3000-5600 |
| K15MP ^(a) | 15 000 | 12 000-21 000 |
| K100MP ^(a) | 100 000 | 80 000-120 000 |
| E4MP ^(a) | 4000 | 3500-5600 |
| E10MP CR ^(a) | 10 000 | 8000-13 000 |
| E3 PREM.LV | | 2.4-3.6 |
| E5 PREM.LV | | 4-6 |
| E6 PREM.LV | | 5-7 |
| E15 PREM.LV | | 12-18 |
| E50 PREM.LV | | 40-60 |
| K3 PREM.LV | | 2.4-3.6 |

^(a) Dow Chemical Company.

Solutions are stable between pH 3-11. Increasing temperature reduces the viscosity of solutions. Hydroxypropyl methylcellulose undergoes a reversible sol to gel transformation upon heating and cooling respectively. The gel point is 50-90°C, depending upon the grade and concentration of material.

Aqueous solutions are comparatively enzyme-resistant, providing good viscosity stability during long-term storage.⁽¹³⁾ However, aqueous solutions are liable to microbial spoilage and should be preserved with an antimicrobial preservative. When used as a viscosity-increasing agent in ophthalmic solutions, benzalkonium chloride is commonly used for this purpose. Aqueous solutions may also be sterilized by autoclaving; the coagulated polymer must be redispersed on cooling by shaking.

Hydroxypropyl methylcellulose powder should be stored in a well-closed container, in a cool, dry, place.

12. Incompatibilities

Hydroxypropyl methylcellulose is incompatible with some oxidizing agents. Since it is nonionic, hydroxypropyl methylcellulose will not complex with metallic salts or ionic organics to form insoluble precipitates.

13. Method of Manufacture

A purified form of cellulose, obtained from cotton linters or wood pulp, is reacted with sodium hydroxide solution to produce a swollen alkali cellulose which is chemically more reactive than untreated cellulose. The alkali cellulose is then treated with chloromethane and propylene oxide to produce methylhydroxypropyl ethers of cellulose. The fibrous reaction product is then purified and ground to a fine, uniform powder or granules.

14. Safety

Hydroxypropyl methylcellulose is widely used as an excipient in oral and topical pharmaceutical formulations. It is also used extensively in cosmetics and food products.

Hydroxypropyl methylcellulose is generally regarded as a nontoxic and nonirritant material although excessive oral consumption may have a laxative effect.⁽¹⁴⁾ The WHO has not specified an acceptable daily intake for hydroxypropyl methylcellulose since the levels consumed were not considered to represent a hazard to health.⁽¹⁵⁾

LD₅₀ (mouse, IP): 5 g/kg⁽¹⁶⁾

LD₅₀ (rat, IP): 5.2 g/kg

15. Handling Precautions

Observe normal precautions appropriate to the circumstances and quantity of material handled. Hydroxypropyl methylcellulose dust may be irritant to the eyes and eye protection is recommended. Excessive dust generation should be avoided to minimize the risks of explosions. Hydroxypropyl methylcellulose is combustible.

16. Regulatory Status

GRAS listed. Accepted as a food additive in Europe. Included in the FDA Inactive Ingredients Guide (ophthalmic preparations, oral capsules, suspensions, syrups and tablets, topical and vaginal preparations). Included in nonparenteral medicines licensed in the UK.

17. Pharmacopeias

China, Eur, Int, Jpn, Pol, and US.

18. Related Substances

Hydroxyethyl cellulose; hydroxypropyl cellulose; hydroxypropyl methylcellulose phthalate; methylcellulose.

19. Comments

Powdered or granular, surface-treated grades of hydroxypropyl methylcellulose are also available which are dispersible in cold water. These are not recommended for oral use.

20. Specific References

1. Chowhan ZT. Role of binders in moisture-induced hardness increase in compressed tablets and its effect on *in vitro* disintegration and dissolution. *J Pharm Sci* 1980; 69: 1-4.
2. Rowe RC. The adhesion of film coatings to tablet surfaces - the effect of some direct compression excipients and lubricants. *J Pharm Pharmacol* 1977; 29: 723-726.
3. Rowe RC. The molecular weight and molecular weight distribution of hydroxypropyl methylcellulose used in the film coating of tablets. *J Pharm Pharmacol* 1980; 32: 116-119.

4. Banker G, Peck G, Jan S, Pirakitikulr P. Evaluation of hydroxypropyl cellulose and hydroxypropyl methyl cellulose as aqueous based film coatings. *Drug Dev Ind Pharm* 1981; 7: 693-716.
5. Okhamafe AO, York P. Moisture permeation mechanism of some aqueous-based film coats. *J Pharm Pharmacol* 1982; 34(Suppl): 53P.
6. Alderman DA, Schulz GJ. Method of making a granular, cold water dispersible coating composition for tablets. US Patent 4816298, 1989.
7. Patell MK. Taste masking pharmaceutical agents. US Patent 4916161, 1990.
8. Hardy JG, Kennerley JW, Taylor MJ, Wilson CG, Davis SS. Release rates from sustained-release buccal tablets in man. *J Pharm Pharmacol* 1982; 34(Suppl): 91P.
9. Hogan JE. Hydroxypropylmethylcellulose sustained release technology. *Drug Dev Ind Pharm* 1989; 15: 975-999.
10. Shah AC, Britten NJ, Olanoff LS, Badalamenti JN. Gel-matrix systems exhibiting bimodal controlled release for oral delivery. *J Controlled Release* 1989; 9: 169-175.
11. Wilson HC, Cuff GW. Sustained release of isomazole from matrix tablets administered to dogs. *J Pharm Sci* 1989; 78: 582-584.
12. Dahl TC, Calderwood T, Bormeth A, Trimble K, Piepmeier E. Influence of physicochemical properties of hydroxypropyl methylcellulose on naproxen release from sustained release matrix tablets. *J Controlled Release* 1990; 14: 1-10.
13. Banker G, Peck G, Williams E, Taylor D, Pirakitikulr P. Microbiological considerations of polymer solutions used in aqueous film coating. *Drug Dev Ind Pharm* 1982; 8: 41-51.
14. Final report on the safety assessment of hydroxyethylcellulose, hydroxypropylcellulose, methylcellulose, hydroxypropyl methylcellulose and cellulose gum. *J Am Coll Toxicol* 1986; 5(3): 1-60.
15. FAO/WHO. Evaluation of certain food additives and contaminants: thirty-fifth report of the joint FAO/WHO expert committee on food additives. *Tech Rep Ser Wld Hlth Org* 1990; No. 789.
16. Sweet DV, editor. Registry of Toxic Effects of Chemical Substances. Cincinnati, US Department of Health, 1987.

21. General References

- Doelker E. Cellulose derivatives. *Adv Polymer Sci* 1993; 107: 199-265.
- Dow Chemical Company. Technical literature: *Methocel*, 1993.
- Malamataris S, Karidas T, Goidas P. Effect of particle size and sorbed moisture on the compression behavior of some hydroxypropyl methylcellulose (HPMC) polymers. *Int J Pharmaceutics* 1994; 103: 205-215.
- Papadimitriou E, Buckton G, Efentakis M. Probing the mechanisms of swelling of hydroxypropylmethylcellulose matrices. *Int J Pharmaceutics* 1993; 98: 57-62.
- Parab PV, Nayak MP, Ritschel WA. Influence of hydroxypropyl methylcellulose and of manufacturing technique on *in vitro* performance of selected antacids. *Drug Dev Ind Pharm* 1985; 11: 169-185.
- Radebaugh GW, Murtha JL, Julian TN, Bondi JN. Methods for evaluating the puncture and shear properties of pharmaceutical polymeric films. *Int J Pharmaceutics* 1988; 45: 39-46.
- Rowe RC. Materials used in the film coating of oral dosage forms. In: Florence AT, editor. *Critical Reports on Applied Chemistry*, volume 6. Oxford, Blackwell Scientific Publications, 1984; 1-36.
- Sebert P, Andrianoff N, Rollet M. Effect of gamma irradiation on hydroxypropylmethylcellulose powders: consequences on physical, rheological and pharmacotechnical properties. *Int J Pharmaceutics* 1993; 99: 37-42.
- Shin-Etsu Chemical Co Ltd. Technical literature: *Metolose*, 1977.
- Shin-Etsu Chemical Co Ltd. Technical literature: *Pharmacoat* hydroxypropyl methylcellulose, 1990.
- Wan LSC, Heng PWS, Wong LF. The effect of hydroxypropylmethylcellulose on water penetration into a matrix system. *Int J Pharmaceutics* 1991; 73: 111-116.

22. Authors

RJ Harwood.

Phenylethyl Alcohol

1. Nonproprietary Names

USP: Phenylethyl alcohol

2. Synonyms

Benzeneethanol; benzyl carbinol; benzylmethanol; β -hydroxyethyl benzene; phenethanol; β -phenylethyl alcohol; 2-phenylethyl alcohol; phenylethanol; PEA.

3. Chemical Name and CAS Registry Number


2-Phenylethanol [60-12-8]

4. Empirical Formula Molecular Weight

$C_8H_{10}O$

122.17

5. Structural Formula



6. Functional Category

Antimicrobial preservative.

7. Applications in Pharmaceutical Formulation or Technology

Phenylethyl alcohol is used as an antimicrobial preservative in nasal, ophthalmic, and otic formulations at 0.25-0.5% v/v concentration; it is generally used in combination with other preservatives.⁽¹⁻³⁾ Phenylethyl alcohol has also been used on its own as an antimicrobial preservative at concentrations up to 1% v/v in topical preparations. At this concentration, mycoplasmas are inactivated within 20 minutes although enveloped viruses are resistant.⁽⁴⁾ Phenylethyl alcohol is also used in flavors and as a perfumery component, especially in rose perfumes.

8. Description

Phenylethyl alcohol is a clear, colorless liquid with an odor of rose oil. It has a burning taste which irritates and then anesthetizes mucous membranes.

9. Pharmacopeial Specifications

| Test | USP |
|-----------------------------|----------------|
| Identification | + |
| Specific gravity | 1.017-1.020 |
| Refractive index | 1.531-1.534 |
| Residue on ignition | $\leq 0.005\%$ |
| Chlorinated compounds | + |
| Aldehyde | + |
| Organic volatile impurities | + |

10. Typical Properties

Antimicrobial activity: phenylethyl alcohol has moderate antimicrobial activity although it is relatively slow acting; it is not sufficiently active to be used alone.⁽⁵⁾ Greatest activity occurs at less than pH 5; it is inactive above pH 8. Synergistic effects have been reported when combined with benzalkonium chloride, chlorhexidine gluconate or diacetate, polymyxin B sulfate, and phenylmercuric nitrate.⁽⁶⁻¹⁰⁾ With either benzalkonium chloride or chlorhexidine, synergistic effects were observed against *Pseudomonas aeruginosa* and apparently additive effects against Gram-positive organisms. With phenylmercuric nitrate, the effect was additive against *Pseudomonas aeruginosa*. Additive effects against *Pseudomonas cepacia* in combination with either benzalkonium chloride or chlorhexidine have also been reported.⁽¹¹⁾ See also Section 12.

Bacteria: fair activity against Gram-positive bacteria; for *Staphylococcus aureus*, the minimum inhibitory concentration (MIC) may be more than 5 mg/mL. Greater activity is shown against Gram-negative organisms.⁽¹²⁾ Typical MIC values are: *Salmonella typhi* 1.25 mg/mL; *Pseudomonas aeruginosa* 2.5 mg/mL; *Escherichia coli* 5.0 mg/mL.

Fungi: poor activity against molds and fungi.

Spores: inactive, e.g., at 0.6% v/v concentration, reported to be ineffective against spores of *Bacillus stearothermophilus* at 100°C for 30 minutes.

Boiling point: 219-221°C

Melting point: -27°C

Partition coefficients:

Chloroform: water = 15.2;

Heptane: water = 0.58;

Octanol: water = 21.5.

Flash point: 102°C (open cup)

Solubility:

| Solvent | Solubility at 20°C |
|-------------------|--------------------|
| Benzyl benzoate | Very soluble |
| Chloroform | Very soluble |
| Diethyl phthalate | Very soluble |
| Ethanol (95%) | Very soluble |
| Ether | Very soluble |
| Fixed oils | Very soluble |
| Glycerin | Very soluble |
| Mineral oil | Slightly soluble |
| Propylene glycol | Very soluble |
| Water | 1 in 60 |

11. Stability and Storage Conditions

Phenylethyl alcohol is stable in bulk, but is volatile and sensitive to light and oxidizing agents. It is reasonably stable in both acidic and alkaline solutions. Aqueous solutions may be sterilized by autoclaving. If stored in low-density polyethylene containers, phenylethyl alcohol may be absorbed by the containers. Losses to polypropylene containers have been reported to be insignificant over 12 weeks at 30°C. Sorption to rubber closures is generally small.

The bulk material should be stored in a well-closed container, protected from light, in a cool, dry, place.

12. Incompatibilities

Incompatible with oxidizing agents and protein, e.g., serum. Phenylethyl alcohol is partially inactivated by polysorbates, although this is not as great as the reduction in antimicrobial activity that occurs with parabens and polysorbates.⁽¹³⁾

13. Method of Manufacture

Phenylethyl alcohol is prepared either by reduction of ethyl phenylacetate with sodium in absolute alcohol; hydrogenation of phenylacetaldehyde in the presence of a nickel catalyst; or by addition of ethylene oxide or ethylene chlorohydrin to phenylmagnesium bromide, followed by hydrolysis. Phenylethyl alcohol also occurs naturally in a number of essential oils, especially rose oil.

14. Safety

Phenylethyl alcohol has been used as an antimicrobial preservative in parenteral, topical, otic, nasal, and ophthalmic preparations and is generally regarded as a nontoxic and nonirritant material. However, at the concentration used to preserve eye-drops (about 0.5% v/v) or above, eye irritation may occur.⁽¹⁴⁾

LD₅₀ (mouse, IP): 0.2 g/kg⁽¹⁵⁾

LD₅₀ (mouse, oral): 0.8 g/kg

LD₅₀ (rabbit, skin): 0.79 g/kg

LD₅₀ (rat, oral): 1.79 g/kg

15. Handling Precautions

Observe normal precautions appropriate to the circumstances and quantity of material handled. Eye protection and gloves are recommended.

16. Regulatory Status

Included in the FDA Inactive Ingredients Guide (nasal, ophthalmic, and otic preparations). Included in nonparenteral medicines licensed in the UK.

17. Pharmacopeias

Pol and US.

18. Related Substances

—

19. Comments

—

20. Specific References

- Goldstein SW. Antibacterial agents in compounded ophthalmic solutions. *J Am Pharm Assoc (Pract Pharm)* 1953; 14: 498-524.
- Heller WM, Foss NE, Shay DE, Ichniowski CT. Preservatives in solutions. *J Am Pharm Assoc (Pract Pharm)* 1955; 16: 29-36.
- Hodges NA, Denyer SP, Hanlon GW, Reynolds JP. Preservative efficacy tests on formulated nasal products: reproducibility and factors affecting preservative activity. *J Pharm Pharmacol* 1996; 48: 1237-1242.
- Staal SP, Rowe WP. Differential effect of phenylethyl alcohol on mycoplasmas and enveloped viruses. *J Virol* 1974; 14: 1620-1622.
- Kohn SR, Gershenfeld L, Barr M. Effectiveness of antibacterial agents presently employed in ophthalmic preparations as preservatives against *Pseudomonas aeruginosa*. *J Pharm Sci* 1963; 52: 967-974.
- Richards RME, McBride RJ. Cross-resistance in *Pseudomonas aeruginosa* resistant to phenylethanol. *J Pharm Sci* 1972; 61: 1075-1077.
- Richards RME, McBride RJ. The preservation of ophthalmic solutions with antibacterial combinations. *J Pharm Pharmacol* 1972; 24: 145-148.
- Richards RME, McBride RJ. Effect of 3-phenylpropan-1-ol, 2-phenylethanol, and benzyl alcohol on *Pseudomonas aeruginosa*. *J Pharm Sci* 1973; 62: 585-587.
- Richards RME, McBride RJ. Enhancement of benzalkonium chloride and chlorhexidine acetate activity against *Pseudomonas aeruginosa* by aromatic alcohols. *J Pharm Sci* 1973; 62: 2035-2037.
- Richards RME, McBride RJ. Antipseudomonal effect of polymyxin and phenylethanol. *J Pharm Sci* 1974; 63: 54-56.
- Richards RME, Richards JM. *Pseudomonas cepacia* resistance to antibacterials. *J Pharm Sci* 1979; 68: 1436-1438.
- Lilley BD, Brewer JH. The selective antibacterial action of phenylethyl alcohol. *J Am Pharm Assoc (Sci)* 1953; 42: 6-8.
- Bahal CK, Kostenbauder HB. Interaction of preservatives with macromolecules V: binding of chlorobutanol, benzyl alcohol, and phenylethyl alcohol by nonionic agents. *J Pharm Sci* 1964; 53: 1027-1029.
- Boer Y. Irritation by eyedrops containing 2-phenylethanol. *Pharm Weekbl (Sci)* 1981; 3: 826-827.
- Sweet DV, editor. Registry of Toxic Effects of Chemical Substances. Cincinnati, US Department of Health, 1987.

21. General References

Silver S, Wendt L. Mechanism of action of phenylethyl alcohol: breakdown of the cellular permeability barrier. *J Bacteriol* 1967; 93: 560-566.

22. Authors

PJ Weller.

Polyoxyethylene Sorbitan Fatty Acid Esters

1. Nonproprietary Names

BP: Polysorbates 20, 60, and 80

JP: Polysorbate 80

PhEur: Polysorbatum 20, 60, and 80

USP: Polysorbates 20, 40, 60, and 80

2. Synonyms

Synonyms of selected polysorbates are shown below, *see also* Section 3.

| Polysorbate | Synonym |
|----------------|---|
| Polysorbate 20 | <i>Armotan PML 20; Capmul POE-L; Crillet 1; Drewmulse; POE-SML; Durfax 20; E432; Glycosperse L-20; Hodag PSML-20; Lamesorb SML-20; Liposorb L-20; Liposorb L-20K; Montanox 20; Nissan Nonion LT-221; Norfox Sorbo T-20; Sorbax PML-20; Sorgen TW-20; sorbitan monododecanoate; T-Maz 20 T-Maz 20K; poly(oxy-1,2-ethanediyl) derivatives; polyoxyethylene 20 laurate; Protasorb L-20; Tween 20.</i> |
| Polysorbate 21 | <i>Crillet 11; Hodag PSML-4; Protasorb L-5; Tween 21.</i> |
| Polysorbate 40 | <i>Crillet 2; E434; Glycosperse S-20; Hodag PSMP-20; Lamesorb SMP-20; Liposorb P-20; Lonzest SMP-20; Montanox 40; Protasorb P-20; sorbitan monohexadecanoate; poly(oxy-1,2-ethanediyl) derivatives; Sorbax PMP-20; Tween 40.</i> |
| Polysorbate 60 | <i>Atlas 70K; Atlas Armotan PMS 20; Capmul POE-S; Crillet 3; Drewpone 60K; Durfax 60; Durfax 60K; Emrite 6125; E435; Glycosperse S-20; Glycosperse S-20FG; Glycosperse S-20FKG; Hodag PSMS-20; Hodag SVS-18; Lamsorb SMS-20; Liposorb S-20; Liposorb S-20K; Lonzest SMS-20; Nikkol TS-10; Norfox SorboT-60 Montanox 60; Polycon T 60 K; polyoxyethylene 20 stearate; sorbitan monooctadecanoate poly(oxy-1,2-ethanediyl) derivatives; Protasorb S-20; Sorbax PMS-20; T-Maz 60; T-Max 60KHS; Tween 60; Tween 60K; Tween 60 VS.</i> |
| Polysorbate 61 | <i>Crillet 31; Hodag PSMS-4; Protasorb S-4; Tween 61.</i> |
| Polysorbate 65 | <i>Alkamuls PSTS-20; Crillet 35; E436; Glycosperse TS-20; Glycosperse TS-20 FG; Glycosperse TS-20 KFG; Hodag PSTS-20; Lamesorb STS-20; Liposorb TS-20; Liposorb TS-20K; Lanzet STS-20; Montanox 65; sorbitan trioctadecanoate poly(oxy-1,2-ethanediyl) derivatives; Protasorb STS-20; Sorbax PTS-20; T-Maz 65K; Tween 65; Tween 65K; Tween 65VS.</i> |

(Continued)

| Polysorbate | Synonym |
|-----------------|---|
| Polysorbate 80 | <i>Atlas E; Armotan PMO 20; Capmul POE-O; Crillet 4; Crillet 50; Drewmulse POE-SMO; Drewpone 80K; Durfax 80; Durfax 80K; Emrite 6120; E433; Glycosperse O-20; Hodag PSMO-20; Liposorb O-20; Liposorb O-20K; Montanox 80; polyoxyethylene 20 oleate; (Z)-sorbitan mono-9-octadecenoate poly(oxy-1,2-ethanediyl) derivatives; Protasorb O-20; Tween 80.</i> |
| Polysorbate 81 | <i>Crillet 41; Hetsorb O-5; Hodag PSMO-5; sorbitan mono-9-octadecenoate poly(oxy-1,2-ethanediyl) derivatives; Protasorb O-5; Sorbax PMO-5; T-Maz 81; Tween 81.</i> |
| Polysorbate 85 | <i>AlkamulsPSTO-20; Crillet 45; Glycosperse TO-20; Hodag PSTO-20; Lonzest STO-20; Liposorb TO-20; Montanox 85; sorbitan tri-9-octadecenoate poly(oxy-1,2-ethanediyl) derivatives; Protasorb TO-20; Sorbax PTO-20; Tween 85.</i> |
| Polysorbate 120 | <i>Crillet 6.</i> |

3. Chemical Names and CAS Registry Numbers

See Table I.

Table I: Chemical name and CAS Registry Number of selected polysorbates.

| Polysorbate | Chemical name | CAS number |
|-----------------|---|--------------|
| Polysorbate 20 | Polyoxyethylene 20 sorbitan monolaurate | [9005-64-5] |
| Polysorbate 21 | Polyoxyethylene (4) sorbitan monolaurate | [9005-64-5] |
| Polysorbate 40 | Polyoxyethylene 20 sorbitan monopalmitate | [9005-66-7] |
| Polysorbate 60 | Polyoxyethylene 20 sorbitan monostearate | [9005-67-8] |
| Polysorbate 61 | Polyoxyethylene (4) sorbitan monostearate | [9005-67-8] |
| Polysorbate 65 | Polyoxyethylene 20 sorbitan tristearate | [9005-71-4] |
| Polysorbate 80 | Polyoxyethylene 20 sorbitan monooleate | [9005-65-6] |
| Polysorbate 81 | Polyoxyethylene (5) sorbitan monooleate | [9005-65-6] |
| Polysorbate 85 | Polyoxyethylene 20 sorbitan trioleate | [9005-70-3] |
| Polysorbate 120 | Polyoxyethylene 20 sorbitan monoisostearate | [66794-58-9] |



4. Empirical Formula Molecular Weight

Approximate molecular weights for selected polysorbates are shown in Table II.

Table II: Empirical formula and molecular weight of selected polysorbates.

| Polysorbate | Formula | Molecular weight |
|-----------------|---|------------------|
| Polysorbate 20 | C ₅₈ H ₁₁₄ O ₂₆ | 1128 |
| Polysorbate 21 | C ₂₆ H ₅₀ O ₁₀ | 523 |
| Polysorbate 40 | C ₆₂ H ₁₂₂ O ₂₆ | 1284 |
| Polysorbate 60 | C ₆₄ H ₁₂₆ O ₂₆ | 1312 |
| Polysorbate 61 | C ₃₂ H ₆₂ O ₁₀ | 607 |
| Polysorbate 65 | C ₁₀₀ H ₁₉₄ O ₂₈ | 1845 |
| Polysorbate 80 | C ₆₄ H ₁₂₄ O ₂₆ | 1310 |
| Polysorbate 81 | C ₃₄ H ₆₄ O ₁₁ | 649 |
| Polysorbate 85 | C ₁₀₀ H ₁₈₈ O ₂₈ | 1839 |
| Polysorbate 120 | C ₆₄ H ₁₂₆ O ₂₆ | 1312 |

5. Structural Formula



w + x + y + z = 20 (Polysorbate 20, 40, 60, 65, 80, and 85)
 w + x + y + z = 5 (Polysorbate 81)
 w + x + y + z = 4 (Polysorbate 21 and 61)
 R = fatty acid

6. Functional Category

Emulsifying agent; nonionic surfactant; solubilizing agent; wetting, dispersing/suspending agent.

7. Applications in Pharmaceutical Formulation or Technology

Polyoxyethylene sorbitan fatty acid esters (polysorbates) are a series of partial fatty acid esters of sorbitol and its anhydrides copolymerized with approximately 20, 5, or 4 moles of ethylene oxide for each mole of sorbitol and its anhydrides. The resulting product is therefore a mixture of molecules of varying sizes rather than a uniform mixture of a single chemical.

Polysorbates containing 20 units of oxyethylene are hydrophilic nonionic surfactants which are used widely as emulsifying agents in the preparation of stable oil-in-water pharmaceutical emulsions. They may also be used as solubi-

lizing agents for a variety of substances including essential oils and oil-soluble vitamins, and as wetting agents in the formulation of oral and parenteral suspensions. Recently they have been found to be useful in improving the oral bioavailability of drug molecules that are substrates for p-glycoprotein.⁽¹⁾

Polysorbates are also widely used in cosmetics and food products.

| Use | Concentration (%) |
|--|-------------------|
| Emulsifying agent | |
| Used alone in oil-in-water emulsions | 1-15 |
| Used in combination with hydrophilic emulsifiers in oil-in-water emulsions | 1-10 |
| Used to increase the water-holding properties of ointments | 1-10 |
| Solubilizing agent | |
| For poorly soluble active constituents in lipophilic bases | 1-10 |
| Wetting agent | |
| For insoluble active constituents in lipophilic bases | 0.1-3 |

8. Description

Polysorbates have a characteristic odor and a warm, somewhat bitter taste. Their colors and physical forms at 25°C are shown below in Table III, although it should be noted that the absolute intensity of the products may vary from batch to batch and manufacturer to manufacturer.

Table III: Color and physical form of selected polysorbates at 25°C.

| Polysorbate | Color and form at 25°C |
|-----------------|------------------------|
| Polysorbate 20 | Yellow oily liquid |
| Polysorbate 21 | Yellow oily liquid |
| Polysorbate 40 | Yellow oily liquid |
| Polysorbate 60 | Yellow oily liquid |
| Polysorbate 61 | Tan solid |
| Polysorbate 65 | Tan solid |
| Polysorbate 80 | Yellow oily liquid |
| Polysorbate 81 | Amber liquid |
| Polysorbate 85 | Amber liquid |
| Polysorbate 120 | Yellow liquid |

9. Pharmacopeial Specifications

| Test | JP | PhEur | USP |
|-------------------------------|-------|--------|--------|
| Identification | | | |
| Polysorbate 20 | — | + | + |
| Polysorbate 40 ^(a) | — | — | + |
| Polysorbate 60 | — | + | + |
| Polysorbate 80 | + | + | + |
| Saponification value | | | |
| Polysorbate 20 | — | 40-50 | 40-50 |
| Polysorbate 40 ^(a) | — | — | 41-52 |
| Polysorbate 60 | — | 45-55 | 45-55 |
| Polysorbate 80 | 45-55 | 45-55 | 45-55 |
| Hydroxyl value | | | |
| Polysorbate 20 | — | 95-108 | 96-108 |
| Polysorbate 40 ^(a) | — | — | 89-105 |
| Polysorbate 60 | — | 81-96 | 81-96 |
| Polysorbate 80 | — | 65-80 | 65-80 |

(Continued)

| Test | JP | PhEur | USP |
|-------------------------------|----------------------------|----------|----------------------------|
| Water | | | |
| Polysorbate 20 | — | ≤ 3.0% | ≤ 3.0% |
| Polysorbate 40 ^(a) | — | — | ≤ 5.0% |
| Polysorbate 60 | — | ≤ 3.0% | ≤ 3.0% |
| Polysorbate 80 | — | ≤ 3.0% | ≤ 3.0% |
| Residue on ignition | | | |
| Polysorbate 20 | — | — | ≤ 0.25% |
| Polysorbate 40 ^(a) | — | — | ≤ 0.25% |
| Polysorbate 60 | — | — | ≤ 0.25% |
| Polysorbate 80 | — | — | ≤ 0.25% |
| Sulfated ash | | | |
| Polysorbate 20 | — | ≤ 0.2% | — |
| Polysorbate 60 | — | ≤ 0.2% | — |
| Polysorbate 80 | — | ≤ 0.2% | — |
| Arsenic | | | |
| Polysorbate 20 | — | — | ≤ 1 ppm |
| Polysorbate 40 ^(a) | — | — | ≤ 1 ppm |
| Polysorbate 60 | — | — | ≤ 1 ppm |
| Polysorbate 80 | — | — | ≤ 1 ppm |
| Heavy metals | | | |
| Polysorbate 20 | — | ≤ 10 ppm | ≤ 0.001% |
| Polysorbate 40 ^(a) | — | — | ≤ 0.001% |
| Polysorbate 60 | — | ≤ 10 ppm | ≤ 0.001% |
| Polysorbate 80 | ≤ 20 ppm | ≤ 10 ppm | ≤ 0.001% |
| Acid value | | | |
| Polysorbate 20 | — | ≤ 2.0 | ≤ 2.2 |
| Polysorbate 40 ^(a) | — | — | ≤ 2.2 |
| Polysorbate 60 | — | ≤ 2.0 | ≤ 2.2 |
| Polysorbate 80 | ≤ 2.0 | ≤ 2.0 | ≤ 2.2 |
| Iodine value | | | |
| Polysorbate 20 | — | ≤ 5.0 | — |
| Polysorbate 40 | — | — | — |
| Polysorbate 60 | — | ≤ 5.0 | — |
| Polysorbate 80 | 19-24 | 18-24 | — |
| Reducing substances | | | |
| Polysorbate 20 | — | + | — |
| Polysorbate 60 | — | + | — |
| Polysorbate 80 | — | + | — |
| Specific gravity | | | |
| Polysorbate 20 | — | 1.10 | — |
| Polysorbate 60 | — | 1.10 | — |
| Polysorbate 80 | 1.005-1.095 | 1.08 | 1.06-1.09 |
| Viscosity at 25°C | | | |
| Polysorbate 80 | 345-445 mm ² /s | — | 300-500 mm ² /s |

^(a) Note that the PhEur contains monographs for polysorbate 20, 60, and 80; while the USP contains monographs for polysorbate 20, 40, 60, and 80.

10. Typical Properties

Acid value: see Table IV.

Acidity/alkalinity: pH = 6.0-8.0 for a 5% w/v aqueous solution.

Flash point: 149°C

HLB value: see Table V.

Hydroxyl value: see Table IV.

Moisture content: see Table IV.

Saponification value: see Table IV.

Solubility: see Table VI.

Specific gravity: see Table V.

Surface tension: for 0.1% w/v solutions, see Table VII.

Viscosity (dynamic): see Table V.

Table IV: Typical properties of selected polysorbates.

| Polysorbate | Acid value (%) | Hydroxyl value | Moisture content | Saponification value |
|-----------------|----------------|----------------|------------------|----------------------|
| Polysorbate 20 | 2.0 | 96-108 | 3.0 | 40-50 |
| Polysorbate 21 | 3.0 | 225-255 | 3.0 | 100-115 |
| Polysorbate 40 | 2.0 | 90-105 | 3.0 | 41-52 |
| Polysorbate 60 | 2.0 | 81-96 | 3.0 | 45-55 |
| Polysorbate 61 | 2.0 | 170-200 | 3.0 | 95-115 |
| Polysorbate 65 | 2.0 | 44-60 | 3.0 | 88-98 |
| Polysorbate 80 | 2.0 | 65-80 | 3.0 | 45-55 |
| Polysorbate 81 | 2.0 | 134-150 | 3.0 | 96-104 |
| Polysorbate 85 | 2.0 | 39-52 | 3.0 | 80-95 |
| Polysorbate 120 | 2.0 | 65-85 | 5.0 | 40-50 |

Table V: Typical properties of selected polysorbates.

| Polysorbate | HLB value | Specific gravity at 25°C | Viscosity (mPa s) |
|-----------------|-----------|--------------------------|-------------------|
| Polysorbate 20 | 16.7 | 1.1 | 400 |
| Polysorbate 21 | 13.3 | 1.1 | 500 |
| Polysorbate 40 | 15.6 | 1.08 | 500 |
| Polysorbate 60 | 14.9 | 1.1 | 600 |
| Polysorbate 61 | 9.6 | 1.06 | solid |
| Polysorbate 65 | 10.5 | 1.05 | solid |
| Polysorbate 80 | 15.0 | 1.08 | 425 |
| Polysorbate 81 | 10.0 | — | 450 |
| Polysorbate 85 | 11.0 | 1.00 | 300 |
| Polysorbate 120 | 14.9 | — | — |

Table VI: Solubilities of selected polysorbates in various solvents.

| Polysorbate | Solvent | | | |
|-----------------|---------|-------------|---------------|-------|
| | Ethanol | Mineral oil | Vegetable oil | Water |
| Polysorbate 20 | S | I | I | S |
| Polysorbate 21 | S | I | I | D |
| Polysorbate 40 | S | I | I | S |
| Polysorbate 60 | S | I | I | S |
| Polysorbate 61 | SW | SW | SWT | D |
| Polysorbate 65 | SW | SW | DW | D |
| Polysorbate 80 | S | I | I | S |
| Polysorbate 81 | S | S | ST | D |
| Polysorbate 85 | S | I | ST | D |
| Polysorbate 120 | S | I | I | S |

D = dispersible; I = insoluble; S = soluble;

T = turbid; W = on warming.

Table VII: Surface tension of related polysorbates.

| Polysorbate | Surface tension at 20°C (mN/m) |
|----------------|--------------------------------|
| Polysorbate 21 | 34.7 |
| Polysorbate 40 | 41.5 |
| Polysorbate 60 | 42.5 |
| Polysorbate 61 | 41.5 |
| Polysorbate 80 | 42.5 |
| Polysorbate 85 | 41.0 |

11. Stability and Storage Conditions

Polysorbates are stable to electrolytes and weak acids and bases; gradual saponification occurs with strong acids and bases. The oleic acid esters are sensitive to oxidation. Polysorbates are hygroscopic and should be examined for water content prior to use and dried if necessary. Also in common with other polyoxyethylene surfactants prolonged storage can lead to the formation of peroxides.

Polysorbates should be stored in a well-closed container, protected from light, in a cool, dry, place.

12. Incompatibilities

Discoloration and/or precipitation occurs with various substances, especially phenols, tannins, tars, and/or tar-like materials. The antimicrobial activity of paraben preservatives is reduced in the presence of polysorbates.⁽²⁾ See Methylparaben.

13. Method of Manufacture

Polysorbates are prepared from sorbitol in a three-step process. Water is initially removed from the sorbitol to form a sorbitan (a cyclic sorbitol anhydride). The sorbitan is then partially esterified with a fatty acid, such as oleic or stearic acid, to yield a hexitan ester. Finally, ethylene oxide is then chemically added in the presence of a catalyst to yield the polysorbate.

14. Safety

Polysorbates are widely used in cosmetics, food products and oral, parenteral, and topical pharmaceutical formulations and are generally regarded as nontoxic and nonirritant materials. There have however been occasional reports of hypersensitivity to polysorbates following their topical use. Polysorbates have also been associated with serious adverse effects, including some deaths, in low-birthweight infants administered intravenously a vitamin E preparation containing a mixture of polysorbate 20 and 80.^(3,4) When heated to decomposition the polysorbates emit acrid smoke and irritating fumes.

The WHO has set an estimated acceptable daily intake for polysorbates 20, 40, 60, 65, and 80, calculated as total polysorbate esters, at up to 25 mg/kg body-weight.⁽⁵⁾

Polysorbate 20: LD₅₀ (rat, oral): 37 g/kg. Moderate toxicity by intraperitoneal, and IV routes. Mildly toxic by ingestion. Human skin irritant.

Polysorbate 21: Moderately toxic by IV.

Polysorbate 40: Moderately toxic by IV.

Polysorbate 60: LD₅₀ (rat, IV): 1.22 g/kg. Moderate toxicity by IV route. Experimental tumorigen, reproductive effects.

Polysorbate 61: Moderately toxic by IV.

Polysorbate 80: LD₅₀ (mouse, oral): 25 g/kg. Moderate toxicity by IV route. Mildly toxic by ingestion. Eye irritation. Experimental tumorigen, reproductive effects. Mutagenic data.

Polysorbate 85: Skin irritant.

15. Handling Precautions

Observe normal precautions appropriate to the circumstances and quantity of material handled. Eye protection and gloves are recommended.

16. Regulatory Status

Polysorbates 60, 65, and 80 are GRAS listed. Polysorbates 20, 40, 60, 65, and 80 are accepted as food additives in Europe. Polysorbates 20, 40, 60, and 80 are included in the FDA Inactive Ingredients Guide (IM, IV, oral, rectal, topical, and vaginal preparations). Polysorbates are included in parenteral and nonparenteral medicines licensed in the UK.

17. Pharmacopeias

| Polysorbate | Pharmacopeia |
|----------------|------------------------------------|
| Polysorbate 20 | Eur, Int, and US. |
| Polysorbate 40 | US. |
| Polysorbate 60 | Eur, Int, Pol, and US. |
| Polysorbate 80 | China, Eur, Int, Jpn, Pol, and US. |

18. Related Substances

Sorbitan esters (sorbitan fatty acid esters).

19. Comments

—

20. Specific References

1. Manoj M, Burton PS, Borchardt T. The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system. *Pharm Res* 1996; 13: 528-534.
2. Blanchard J. Effect of polyols on interaction of paraben preservatives with polysorbate 80. *J Pharm Sci* 1980; 69: 169-173.
3. Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. *Pediatrics* 1986; 77: 593-597.
4. Balistreri WF, Farrell MK, Bove KE. Lessons from the E-Ferol tragedy. *Pediatrics* 1986; 78: 503-506.
5. FAO/WHO. Toxicological evaluation of certain food additives with a review of general principles and of specifications: seventeenth report of the joint FAO/WHO expert committee on food additives. *Tech Rep Ser Wld Hlth Org* 1974; No. 539.

21. General References

- Allen LV, Levinson RS, Robinson C, Lau A. Effect of surfactant on tetracycline absorption across everted rat intestine. *J Pharm Sci* 1981; 70: 269-271.
- Chowhan ZT, Pritchard R. Effect of surfactants on percutaneous absorption of naproxen I: comparisons of rabbit, rat, and human excised skin. *J Pharm Sci* 1978; 67: 1272-1274.
- Donbrow M, et al. Autoxidation of polysorbates. *J Pharm Sci* 1978; 67: 1676-1681.
- Smolinske SC. *Handbook of Food, Drug, and Cosmetic Excipients*. Boca Raton, FL, CRC Press Inc, 1992; 295-301.

22. Authors

MJ Lawrence.

Sodium Chloride

1. Nonproprietary Names

BP: Sodium chloride
 JP: Sodium chloride
 PhEur: Natrii chloridum
 USP: Sodium chloride

2. Synonyms

Chlorure de sodium; cloreto de sódio; common salt; natural halite; rock salt; salt; sea salt; table salt.

3. Chemical Name and CAS Registry Number

Sodium chloride [7647-14-5]

4. Empirical Formula Molecular Weight

NaCl 58.44

5. Structural Formula

NaCl

6. Functional Category

Tablet and capsule diluent; tonicity agent.

7. Applications in Pharmaceutical Formulation or Technology


Sodium chloride is widely used in a variety of parenteral and nonparenteral pharmaceutical formulations. Its primary use, in parenteral and ophthalmic preparations, is to produce isotonic solutions.

Sodium chloride has been used as a lubricant and diluent in capsules and direct-compression tablet formulations in the past.⁽¹⁻⁵⁾ This practice is no longer common. Sodium chloride has also been used as a channeling agent^(6,7) and osmotic agent^(8,9) in the cores of controlled-release tablets, as a porosity modifier in tablet coatings⁽¹⁰⁾ and to control-drug release from microcapsules.^(11,12) The addition of sodium chloride to aqueous spray-coating solutions containing hydroxypropyl cellulose or hypromellose suppressed the agglomeration of crystalline-cellulose particles;⁽¹³⁾ it can also be used to modify drug-release from gels⁽¹⁴⁾ and from multiple emulsions.⁽¹⁵⁾ It may also be used to control micelle size,⁽¹⁶⁻¹⁸⁾ and to adjust the viscosity of polymer dispersions by altering the ionic character of a formulation.^(19,20)

| Use | Concentration (%) |
|---|-------------------|
| Capsule diluent | 10-80 |
| Controlled flocculation of suspensions | Up to 1 |
| Direct compression tablet diluent | 10-80 |
| To produce isotonic solutions in intravenous or ophthalmic preparations | Up to 0.9 |
| Water-soluble tablet lubricant | 5 - 20 |

SEM: 1

Excipient: Sodium chloride, powder
 Manufacturer: Mallinckrodt Speciality Chemicals Co
 Magnification: 600x



8. Description

Sodium chloride occurs as a white crystalline powder or colorless crystals; it has a saline taste. The crystal lattice is a face-centered cubic structure. Solid sodium chloride contains no water of crystallization although, below 0°C, salt may crystallize as a dihydrate.

9. Pharmacopeial Specifications


| Test | JP | PhEur | USP |
|-------------------------------------|------------------------|-----------------------------|---------------------------|
| Identification | + | + | + |
| Appearance of solution | + | + | + |
| Acidity or alkalinity | pH 4.5-7.0 | + | + |
| Loss on drying | ≤ 0.5% | ≤ 0.5% | 0.05% |
| Arsenic | ≤ 2 ppm | ≤ 1 ppm | 1 µg/g |
| Bromides | + | ≤ 50 ppm | ≤ 0.01% |
| Barium | + | + | + |
| Nitrites | — | + | + |
| Aluminum | 0.2 ppm ^(a) | ≤ 0.2 µg/g ^(a) | |
| Magnesium and alkaline earth metals | + | ≤ 100 ppm | ≤ 0.01% |
| Iodide | + | + | + |
| Iron | — | ≤ 2 ppm | ≤ 2 ppm |
| Sulfate | — | ≤ 200 ppm | ≤ 0.02% |
| Ferrocyanides | — | + | + |
| Heavy metals | ≤ 3 ppm | ≤ 5 ppm | ≤ 5 ppm |
| Phosphate | — | ≤ 25 ppm | ≤ 0.0025% |
| Potassium | — | ≤ 500 ppm ^{(a)(b)} | ≤ 0.05% ^{(a)(b)} |
| Organic volatile impurities | — | — | + |
| Bacterial endotoxins | — | ≤ 5 IU/g ^(b) | — |
| Assay (dried basis) | 99.0-100.5% | 99.0-100.5% | ≤ 99.5-≥ 100.5% |

^(a) If for use in peritoneal dialysis, hemodialysis or hemofiltration solutions.


^(b) If for parenteral use.

SEM: 2

Excipient: Sodium chloride, granular
 Manufacturer: Van Waters & Rogers Inc
 Magnification: 120x

**SEM: 3**

Excipient: Sodium chloride, granular
 Manufacturer: Van Waters & Rogers Inc
 Magnification: 600x

**10. Typical Properties****Acidity/alkalinity:**

pH = 6.7-7.3 (saturated aqueous solution)

Angle of repose: 38° for cubic crystals

Boiling point: 1439°C

Compressibility: with sodium chloride powder of less than 30 µm particle size, tablets are formed by plastic deformation. Above this size both plastic deformation and fracture occur.^(1,3,4) See also Fig. 1.

Density:

2.17 g/cm³;

1.20 g/cm³ for saturated aqueous solution.

Density (bulk): 0.93 g/cm³

Density (tapped): 1.09 g/cm³

Freezing point depression:

| Aqueous sodium chloride solution (% w/v) | Freezing point depression (°C) |
|--|--------------------------------|
| 11.69 | 6.90 |
| 17.53 | 10.82 |
| 23.38 | 15.14 |
| 30.39 | 21.12 |

Hardness (Mohs): 2-2.5

Hygroscopicity: hygroscopic above 75% RH.

Melting point: 801°C

Osmolarity: a 0.9% w/v aqueous solution is iso-osmotic with serum.

Refractive index:

$n_D^{20} = 1.343$ for a 1 M aqueous solution.

Solubility:

| Solvent | Solubility at 25°C Unless otherwise stated |
|---------------|--|
| Ethanol | Slightly soluble |
| Ethanol (95%) | 1 in 250 |
| Glycerin | 1 in 10 |
| Water | 1 in 2.8 |
| | 1 in 2.6 at 100°C |




Fig. 1: Compression characteristics of sodium chloride (cubic crystals).⁽³⁾

Tablet diameter = 12 mm.

Vapor pressure:

133.3 Pa at 865°C for solid;

1759.6 Pa at 20°C for a saturated aqueous solution (equivalent to 75.3% RH).

Viscosity:

a 10% w/v solution has a viscosity of 1.19 mPa s (1.19 cP).

11. Stability and Storage Conditions

Aqueous sodium chloride solutions are stable but may cause the separation of glass particles from certain types of glass

containers. Aqueous solutions may be sterilized by autoclaving or filtration. The solid material is stable and should be stored in a well-closed container, in a cool, dry, place.

It has been shown that the compaction characteristics and the mechanical properties of tablets are influenced by the relative humidity of the storage conditions under which sodium chloride was stored.^(21,22)

12. Incompatibilities

Aqueous sodium chloride solutions are corrosive to iron; they also react to form precipitates with silver, lead, and mercury salts. Strong oxidizing agents liberate chlorine from acidified solutions of sodium chloride. The solubility of the antimicrobial preservative methylparaben is decreased in aqueous sodium chloride solutions⁽²³⁾ and the viscosity of carbomer gels and solutions of hydroxyethyl cellulose or hydroxypropyl cellulose is reduced by the addition of sodium chloride.

13. Method of Manufacture

Sodium chloride occurs naturally as the mineral halite. Commercially, it is obtained by the solar evaporation of sea water, by mining or by the evaporation of brine from underground salt deposits.

14. Safety

Sodium chloride is the most important salt in the body for maintaining the osmotic tension of blood and tissues. About 5-12 g of sodium chloride is consumed daily, in the normal adult diet, and a corresponding amount excreted in the urine. As an excipient, sodium chloride may be regarded as an essentially nontoxic and nonirritant material. However, toxic effects following the oral ingestion of 0.5-1.0 g/kg body-weight in adults may occur. The oral ingestion of larger quantities of sodium chloride, e.g., 1000 g in 600 mL of water,⁽²⁴⁾ is harmful and can induce irritation of the gastrointestinal tract, vomiting, hypernatremia, respiratory distress, convulsions, or death.

In rats, the minimum lethal intravenous dose is 2.5 g/kg body-weight.

LD₅₀ (mouse, IP): 6.61 g/kg⁽²⁵⁾

LD₅₀ (mouse, IV): 0.65 g/kg

LD₅₀ (mouse, oral): 4.0 g/kg

LD₅₀ (mouse, SC): 3.0 g/kg

LD₅₀ (rat, oral): 3.0 g/kg

15. Handling Precautions

Observe normal precautions appropriate to the circumstances and quantity of material handled. Sodium chloride evolves a vapor irritating to the eyes if heated to high temperatures.

16. Regulatory Status

GRAS listed. Included in the FDA Inactive Ingredients Guide (injections, inhalations, nasal, ophthalmic, oral, otic, rectal, and topical preparations). Included in nonparenteral and parenteral medicines licensed in the UK.

17. Pharmacopeias

China, Eur, Int, Jpn, Pol, and US.

18. Related Substances

Potassium chloride.

19. Comments

Domestic table salt may contain sodium iodide (as a prophylactic substance against goiter) and agents such as magnesium carbonate, calcium phosphate, or starch, which reduce the hygroscopic characteristics of the salt and maintain the powder in a free-flowing state.

Food-grade dendritic salt, which is porous, can be used as an absorbent for liquid medications, and as a tablet diluent in specific formulations.

Each gram of sodium chloride represents approximately 17.1 mmol of sodium and 17.1 mmol of chloride; 2.54 g of sodium chloride is approximately equivalent to 1 g of sodium.

A saturated solution of sodium chloride can be used as a constant humidity solution; at 25°C, a relative humidity of 75% is produced.

20. Specific References

1. Leigh S, Carless JE, Burt BW. Compression characteristics of some pharmaceutical materials. *J Pharm Sci* 1967; 56: 888-892.
2. Rees JE, Shotton E. Some observations on the ageing of sodium chloride compacts. *J Pharm Pharmacol* 1970; 22: 17S-23S.
3. Shotton E, Obiorah BA. The effect of particle shape and crystal habit on the properties of sodium chloride. *J Pharm Pharmacol* 1973; 25, 37P-43P.
4. Roberts RJ, Rowe RC, Kendall K. Brittle-ductile transitions in die compaction of sodium chloride. *Chem Eng Sci* 1989; 44: 1647-1651.
5. Hammouda Y, Eshra AG, El-Banna, HM. The use of sodium chloride as a directly compressible filler. Part III: Drug-to-filler ratio. *Pharm Ind* 1978; 40(9): 987-992.
6. González-Rodríguez ML, Fernández-Hervás, Caraballo I, Rabasco AM. Design and evaluation of a new central core matrix tablet. *Int J Pharmaceutics* 1997; 146: 175-180.
7. Korsatko-Wabnegg B. Development of press-coated tablets with controlled release effect using poly-D-(-)-3-hydroxybutyric acid (in German). *Pharmazie* 1990; 45: 842-844.
8. Moussa IS, Cartilier LH. Evaluation of crosslinked amylose press-coated tablets for sustained drug delivery. *Int J Pharmaceutics* 1997; 149: 139-149.
9. Özdemir N, Sahin J. Design of a controlled release osmotic pump system of ibuprofen. *Int J Pharmaceutics* 1997; 158: 91-97.
10. Shivanand P, Sprockel OL. A controlled porosity drug delivery system. *Int J Pharmaceutics* 1998; 167: 83-96.
11. Tirkkonen S, Paronen P. Enhancement of drug release from ethylcellulose microcapsules using solid sodium chloride in the wall. *Int J Pharmaceutics* 1992; 88: 39-51.
12. Tirkkonen S, Paronen P. Release of indomethacin from tableted ethylcellulose microcapsules. *Int J Pharmaceutics* 1993; 92: 55-62.
13. Yuasa H, Nakano T, Kanaya Y. Suppression of agglomeration in fluidized bed coating I. Suppression of agglomeration by adding sodium chloride. *Int J Pharmaceutics* 1997; 158: 195-201.
14. Pandit NK, Wang D. Salt effects on the diffusion and release rate of propranolol from poloxamer 407 gels. *Int J Pharmaceutics* 1998; 167: 183-189.

15. Mishra B, Pandit JK. Multiple water-oil-water emulsions as prolonged release formulations of pentazocine. *J Controlled Release* 1990; 14: 53-60.
16. Shah D, Ecanow B, Balagot R. Coacervate formation by inorganic salts with benzalkonium chloride. *J Pharm Sci* 1973; 62: 1741-1742.
17. Richard AJ. Ultracentrifugal study of effect of sodium chloride on micelle size of fusidate sodium. *J Pharm Sci* 1975; 64: 873-875.
18. McDonald C, Richardson C. The effect of added salts on solubilization by a non-ionic surfactant. *J Pharm Pharmacol* 1981; 33: 38-39.
19. Mattha AG. Rheological studies on *Plantago albicans* (Psyllium) seed gum dispersions II: effect of some pharmaceutical additives. *Pharm Acta Helv* 1977; 52: 214-217.
20. Okor RS. The effect of phenol on the electrolyte flocculation of certain polymeric dispersions to thixotropic gels. *Pharm Res* 1993; 10: 220-222.
21. Elamin AA, Alderborn G, Ahlneck C. The effect of pre-compaction processing and storage conditions on powder and compaction properties of some crystalline materials. *Int J Pharmaceutics* 1994; 108: 213-224.
22. Ahlneck C, Alderborn G. Moisture adsorption and tableting. II. The effect on tensile strength and air permeability of the relative humidity during storage of tablets of 3 crystalline materials. *Int J Pharmaceutics* 1989; 56: 143-150.
23. McDonald C, Lindstrom RE. The effect of urea on the solubility of methyl *p*-hydroxybenzoate in aqueous sodium chloride solution. *J Pharm Pharmacol* 1974; 26: 39-45.
24. Calam J, Krasner N, Haqqani M. Extensive gastrointestinal damage following a saline emetic. *Dig Dis Sci* 1982; 27: 936-940.
25. Sweet DV, editor. Registry of Toxic Effects of Chemical Substances. Cincinnati, US Department of Health, 1987.

21. General References

-

22. Authors

CG Cable.

Water

1. Nonproprietary Names

BP: Purified water
 JP: Purified water
 PhEur: Aqua purificata
 USP: Purified water

See also Sections 8 and 18.

2. Synonyms

Aqua; hydrogen oxide.

3. Chemical Name and CAS Registry Number

Water [7732-18-5]

4. Empirical Formula Molecular Weight

H₂O 18.02

5. Structural Formula

H₂O

6. Functional Category

Solvent.

7. Applications in Pharmaceutical Formulation or Technology

Water is the most widely used excipient in pharmaceutical production operations. Specific grades of water are used for particular applications in concentrations up to 100%, see Table I. Purified water and water for injection are also used for cleaning operations during production of pharmaceutical products.

8. Description

The term 'water' is used to describe potable water freshly drawn direct from the public supply and suitable for drinking. The chemical composition of potable water is variable and the nature and concentration of the impurities in it depends upon the source from which it is drawn. Although potable water must be both palatable and safe to drink, for most pharmaceutical applications potable water is purified by distillation, ion exchange treatment, reverse osmosis, or some other suitable process to produce 'purified water'. For certain applications, water with pharmacopeial specifications differing from purified water should be used, e.g., water for injection, see Sections 9 and 20.

Water is a clear, colorless, odorless, and tasteless liquid.

9. Pharmacopeial Specifications

See Table II.

Significant changes to the USP testing of Purified Water and Water for Injection were introduced in the 5th supplement to the USP23. These changes were not intended to tighten specifications but to allow the application of modern rapid analytical techniques and to replace the old semiquantitative methods. The changes involve the introduction of a conductivity test for inorganic con-

Table I: Typical applications of specific grades of water.

| Type | Use |
|------------------------------------|---|
| Bacteriostatic water for injection | Diluent for ophthalmic and multiple-dose injections. |
| Potable water | Public supply suitable for drinking, the purity of which is unlikely to be suitable for use in the manufacture of pharmaceuticals. |
| Purified water | Vehicle and solvent for the manufacture of drug products and pharmaceutical preparations; not suitable for use in the manufacture of parenteral products. |
| Sterile water for inhalation | Diluent for inhalation therapy products. |
| Sterile water for injection | Diluent for injections. |
| Sterile water for irrigation | Diluent for internal irrigation therapy products. |
| Water for injections in bulk | Water for the bulk preparation of medicines for parenteral administration. |

tamination to replace the various chemical tests and the introduction of a Total Organic Carbon test (TOC) to replace the oxidizable substances test. A TOC limit of 500 ppb was selected based on the JP and this was found to be acceptable when applied to pharmaceutical companies throughout the US. The conductivity test is multistaged to allow for CO₂ absorption and temperature effects. Meeting the limits at the first stage precludes the need to test stages 2 and 3; if the results are higher than the limit at stage 1 the sample does not fail if shown to be satisfactory at stage 2 or 3. It is preferable to test TOC on line rather than laboratory testing.

The PhEur has issued a monograph which is comparable to the chemical testing requirements of the USP. Work is currently ongoing to produce a document which harmonizes the quality requirements of purified water in the PhEur, the JP, and the USP.

10. Typical Properties

Boiling point: 100°C

Critical pressure: 22.1 MPa (218.3 atm)

Critical temperature: 374.2°C

Dielectric constant: D²⁵ = 78.54

Dipole moment:

1.76 in benzene at 25°C;

1.86 in dioxane at 25°C.

Ionization constant: 1.008 × 10⁻¹⁴ at 25°C

Latent heat of fusion: 6 kJ/mole (1.436 kcal/mole)

Latent heat of vaporization:

40.7 kJ/mole (9.717 kcal/mole)

Melting point: 0°C

Refractive index: n_D²⁰ = 1.3330

Solubility: miscible with most polar solvents.

Specific gravity: 0.9971 at 25°C.

Specific heat (liquid):

4.184 J/g/°C (1.00 cal/g/°C) at 14°C

Surface tension:

71.97 mN/m (71.97 dynes/cm) at 25°C.

Vapor pressure: 3.17 kPa (23.76 mmHg) at 25°C.

Viscosity (dynamic): 0.89 mPa s (0.89 cP) at 25°C.

Table II: Pharmacopeial specifications of water for different pharmaceutical applications.

| Test | Purified Water in bulk JP | Purified Water in bulk USP | Purified Water in containers PhEur | Water for injection JP | Water for injection PhEur | Water for injection USP | Sterile water for injection PhEur | Sterile water for injection USP | Sterile water for injection USP | Sterile water for inhalation USP | Sterile water for irrigation JP | Sterile water for irrigation USP | Sterile purified water USP |
|-------------------------|---------------------------|----------------------------|------------------------------------|------------------------|---------------------------|-------------------------|-----------------------------------|---------------------------------|---------------------------------|----------------------------------|---------------------------------|----------------------------------|----------------------------|
| Identification | - | + | + | - | - | + | + | + | + | + | - | + | - |
| pH | - | - | - | - | - | - | - | 4.5-7.0 | 4.5-7.0 | 4.5-7.5 | - | 5.0-7.0 | 5.0-7.0 |
| Acid or alkali Chloride | + | - | + | + | - | - | + | - | - | - | + | - | - |
| Sulfate | + | - | + | + | - | - | + | + | + | + | + | + | + |
| Ammonium | + | - | + | + | - | - | + | + | + | + | + | + | + |
| Calcium | - | - | + | - | - | - | - | + | + | + | ≤ 0.05 mg/L | + | + |
| Magnesium | - | - | + | - | - | - | - | - | - | - | - | - | - |
| Nitrate | + | - | + | + | - | - | + | + | + | + | - | + | - |
| Carbon dioxide | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Heavy metals | + | - | + | + | - | - | + | + | + | + | + | + | + |
| Oxidizable substances | + | - | + | + | - | - | + | + | + | + | + | + | + |
| TOC | ≤ 500 ppb | ≤ 500 ppb | ≤ 500 ppb | - | ≤ 500 ppb | ≤ 500 ppb | + | - | - | - | - | - | - |
| Conductivity | ≤ 4.3 µs/cm | 1.25 µs/cm | ≤ 4.3 µs/cm | - | ≤ 1.1 µs/cm | 1.25 µs/cm | + | - | - | - | - | - | - |
| Antimicrobial agents | - | - | - | - | - | - | - | + | + | + | - | - | - |
| Sterility | - | - | - | - | - | - | + | + | + | + | + | + | + |
| Particulate matter | + | - | - | + | - | + | + | + | + | + | + | + | + |
| Microbial contamination | + | ≤ 100 cfu/mL | ≤ 100 cfu/mL | + | ≤ 10 cfu/mL | + | + | + | + | + | + | + | + |
| Bacterial endotoxins | - | - | - | ≤ 0.25 EU/mL | ≤ 0.25 EU/mL | ≤ 0.25 EU/mL | ≤ 0.25 IU/mL | ≤ 0.25 EU/mL | ≤ 0.5 EU/mL | ≤ 0.5 EU/mL | - | ≤ 0.25 EU/mL | - |

Note: + = tested for; - = not tested for.

(a) If volume 100 mL or less.

(b) Containers with nominal volume at 10 mL or less, ≤ 25 µs/cm. If the nominal volume is greater than 10 mL, ≤ 5 µs/cm.

Table III: Storage requirements for different grades of water.

| Type | Storage requirements ^(a) |
|------------------------------------|---|
| Bacteriostatic water for injection | Preserve in single-dose and multiple-dose containers, preferably of Type I or Type II glass, not larger than 30 mL in size. |
| Potable water | Preserve in tightly sealed containers. |
| Purified water | Preserve in tightly sealed containers. If stored in bulk, the conditions of storage should be designed to limit the growth of microorganisms and avoid any other contamination. |
| Sterile water for inhalation | Preserve in single-dose containers, preferably of Type I or Type II glass. |
| Sterile water for injection | Preserve in single-dose containers, preferably of Type I or Type II glass, not more than 1000 mL in size. |
| Water for injection | Preserve in tightly sealed containers. |
| Water for injections in bulk | Collected and stored in conditions designed to prevent growth of microorganisms and avoid any other contamination. |

^(a) To prevent evaporation and to maintain quality.

11. Stability and Storage Conditions

Water is chemically stable in all physical states (ice, liquid, and steam). Water for specific purposes should be stored in an appropriate container, *see* Table III.

12. Incompatibilities

In pharmaceutical formulations, water can react with drugs and other excipients that are susceptible to hydrolysis (decomposition in the presence of water or moisture) at ambient and elevated temperatures.

Water can react violently with alkali metals and rapidly with alkaline metals and their oxides; such as calcium oxide and magnesium oxide. Water also reacts with anhydrous salts to form hydrates of various compositions, and with certain organic materials and calcium carbide.

13. Method of Manufacture

Unlike other excipients water is not purchased from outside suppliers but is manufactured in-house by pharmaceutical companies. The selection of the most appropriate system and the overall design of the system are crucial factors to ensure that water of the correct quality is produced.^(1,14)

To produce potable or drinking water, insoluble matter is first removed from a water supply by coagulation, settling, and filtering processes. Pathogenic microorganisms present are then destroyed by aeration, chlorination, or some other means. Water may also be rendered free of viable pathogenic microorganisms by active boiling for 15-20 minutes. Finally, the palatability of the water is then improved by aeration and charcoal filtration.

The quality attributes of water for injection (WFI) are stricter than for purified water. Consequently the preparation methods typically vary in the last stage to ensure good control of qual-

ity of WFI. Methods for the production of WFI are the subject of current debate. The PhEur believes only distillation would give assurance of consistent supply of the right quality. The USP and the JP however permit the use of reverse osmosis (RO) in addition to distillation and ultrafiltration, agreement is therefore required before a harmonized document can be issued.

Purified water suitable for use in pharmaceutical formulations is usually prepared by purifying potable water by one of several processes, such as: distillation; de-ionization; or reverse osmosis.⁽¹⁻⁷⁾

Distillation: a wide variety of stills are available to produce purified or distilled water. A typical design consists of an evaporator, vapor separator, and compressor. The distill and (raw feed water) is heated in the evaporator to boiling and the vapor produced separated from entrained distill and in the separator. The vapor then enters a compressor where the temperature of the vapors is raised to 107°C. Superheated vapors are then condensed on the outer surface of the tubes of the evaporator containing cool distill and circulating within.

Vapor compression stills of various sizes are commercially available and can be used to produce water of high purity when properly constructed. A high-quality distillate, such as water for injection, can be obtained if the water is first de-ionized. The best stills are constructed of types 304 or 316 stainless steel and coated with pure tin, or are made from chemical-resistant glass.

De-ionization: cationic and anionic ion-exchange resins are used to purify potable water by removing any dissolved ions. Dissolved gases are also removed, while chlorine, in the concentrations generally found in potable water, is destroyed by the resin itself. Some organics and colloidal particles are removed by adsorption and filtration. Resin beds may however foster microbial life and produce pyrogenic effluent unless adequate precautions are taken to prevent contamination. Mixed bed units produce purer water (decreased conductivity) than stills. However, the organic matter content is usually higher. Ion-exchange units are normally used today to treat raw feed water prior to distillation or reverse osmosis processing.

Reverse osmosis: water is forced through a semipermeable membrane in the opposite direction to normal osmotic diffusion. A very small proportion of inorganic salts passes through, but undissolved materials (bacteria and large molecules, such as viruses, pyrogens, and high molecular weight organics) are removed.

Ultra filtration: a permeable membrane is used for mechanical separation. Impurities including endotoxins are removed by the membrane.

14. Safety

Water is the base for many biological life forms, and its safety in pharmaceutical formulations is unquestioned provided it meets standards of quality for potability⁽⁸⁾ and microbial content, *see* Sections 9 and 19. Plain water is considered slightly more toxic upon injection to laboratory animals than physiological salt solutions such as normal saline or Ringer's solution.

Ingestion of excessive quantities of water can lead to water intoxication with disturbances of the electrolyte balance.

Water for injection should be free from pyrogens.

15. Handling Precautions

Observe normal precautions appropriate to the circumstances and quantity of material handled.

16. Regulatory Status

Included in nonparenteral and parenteral medicines licensed in the UK and US.

17. Pharmacopeias

China, Eur, Int, Jpn, Pol, and US.

18. Related Substances

Bacteriostatic water for injection

Pharmacopeias: US.

Comments: the USP describes bacteriostatic water for injection as sterile water for injection which contains one or more suitable antimicrobial agents.

Carbon dioxide-free water

Comments: purified water that has been boiled vigorously for 5 minutes and allowed to cool while protecting it from absorption of atmospheric carbon dioxide.

De-aerated water

Comments: purified water that has been boiled vigorously for 5 minutes and cooled to reduce the air (oxygen) content.

Hard water

Comments: water containing the equivalent to not less than 120 mg/L and not more than 180 mg/L of calcium carbonate.

Soft water

Comments: water containing the equivalent to not more than 60 mg/L of calcium carbonate.

Sterile water for inhalation

Pharmacopeias: US.

Comments: the USP describes sterile water for inhalation as water purified by distillation or by reverse osmosis and rendered sterile. It contains no antimicrobial agents or other added substances, except where used in humidifiers or other similar devices, and where liable to contamination over a period of time.

Sterile water for injection

Pharmacopeias: US.

Comments: the USP describes sterile water for injection as water for injection sterilized and suitably packaged. It contains no antimicrobial agents or other substances.

Sterile water for irrigation

Pharmacopeias: Br and US.

Comments: the USP describes sterile water for irrigation as water for injection sterilized and suitably packaged. It contains no antimicrobial agents or other substances.

Water for injection

Pharmacopeias: China, Eur, Int, Jpn, Pol, and US.

Comments: the USP describes water for injection as water purified by distillation or reverse osmosis. It contains no added substances. The PhEur title is 'water for injections'

and comprises two parts, 'water for injections in bulk' and 'sterilized water for injection'. The PhEur states that water for injections is produced by distillation.

19. Comments

In most pharmacopeias, the term 'water' now refers to purified or distilled water.

Without further purification, 'water' may be unsuitable for certain pharmaceutical applications, e.g., the presence of calcium in water affects the viscosity and gel strength of algin and pectin dispersions, while the use of potable water affects the clarity and quality of cough mixtures, and the stability of antibiotic liquid preparations.

Water commonly contains salts of aluminum, calcium, iron, magnesium, potassium, sodium, and zinc. Toxic substances such as arsenic, barium, cadmium, chromium, cyanide, lead, mercury, and selenium may constitute a danger to health if present in excessive amounts. Ingestion of water containing high amounts of calcium and nitrate is also contra-indicated. National standards generally specify the maximum limits for these inorganic substances in potable water. Limits have also been placed on microorganisms, detergents, phenolics, chlorinated phenolics, and other organic substances. The WHO,⁽⁹⁾ and other national bodies, have issued guidelines for water quality although many countries have their own standards for water quality embodied in specific legislation.⁽¹⁰⁾ See Table IV.

Table IV: Limits for inorganic substances in potable water (mg/L).

| Contaminant | UK (mg/L) | WHO (mg/L) |
|-------------------------------|--------------|---------------|
| Aluminum | 0.2 | 0.2 |
| Ammonium | 0.5 | — |
| Antimony | 0.01 | — |
| Arsenic | 0.05 | 0.05 |
| Barium | 1.0 | No limit |
| Beryllium | — | No limit |
| Boron | 2.0 | — |
| Cadmium | 0.005 | 0.005 |
| Calcium | 250 | — |
| Chloride | 400 | 250 |
| Chromium | 0.05 | 0.05 |
| Copper | 3.0 | 1.0 |
| Cyanide | 0.05 | 0.1 |
| Fluoride | 1.5 | 1.5 |
| Iron | 0.2 | 0.3 |
| Lead | 0.05 | 0.05 |
| Magnesium | 50 | — |
| Manganese | 0.05 | 0.1 |
| Mercury | 0.001 | 0.001 |
| Nickel | 0.05 | No limit |
| Nitrate (as N) | — | 10 |
| Nitrate (as NO ₃) | 50 | — |
| Nitrite (as NO ₂) | 0.1 | — |
| Phosphorus | 2.2 | — |
| Potassium | 12 | — |
| Selenium | 0.01 | 0.01 |
| Silver | 0.01 | No limit |
| Sodium | 150 | 200 |
| Sulfate | 250 | 400 |
| Zinc | 5.0 | 5.0 |

Control of microbiological contamination is critical for waters used in preparation of pharmaceuticals as proliferation of microorganisms can potentially occur during all stages of manufacture, storage, or distribution. Suitable control is achieved by ensuring that the water system is well designed and well maintained. Purified water which is produced, stored, and circulated at ambient temperatures is susceptible to the establishment of biofilms; therefore, frequent monitoring, high usage, correct flow rate, and appropriate sanitization are all factors which require consideration to ensure that water is satisfactory.⁽¹²⁾

In order to demonstrate correct microbiological quality is achieved monitoring of the whole system is essential. For WFI the recommended methodology is membrane filtration (0.45 µm) as a large sample size (100-300 mL) is required. For purified water, membrane filtration or plate count methods are typically used depending on the quality requirements of the system. It is important to set appropriate target, alert, and action limits to serve as an indication of action required to bring the quality of water back under control. It is recognized that limits are not intended as pass/fail criteria for water or product batches; however, an investigation regarding the implications should be conducted.⁽¹³⁾

Validation is conducted to provide a high level of assurance that the water production and distribution system will consistently produce water conforming to a defined quality specification. The validation process serves to qualify the design (DQ), installation (IQ), operation (OQ), and performance (PQ) of the system. The extent of monitoring data required should be defined with consideration given to whether validation to FDA guidelines is required.⁽¹³⁾ It is also important to have an ongoing control program with respect to maintenance and periodic reviews of the performance of the water system.

20. Specific References

1. Thomas WH, Harvey H. Achieving purity in pharmaceutical water. *Mfg Chem Aerosol News* 1976; 47(10): 32, 36, 39, 40.
2. Honeyman T. Purified water for pharmaceuticals. *Mfg Chem* 1987; 58(3): 53, 54, 57, 59.
3. Cross J. Treating waters for the pharmaceutical industry. *Mfg Chem* 1988; 59(3): 34-35.
4. Cross J. Steam sterilisable ultrafiltration membranes. *Mfg Chem* 1989; 60(3): 25-27.
5. Horry JM, Cross JR. Purifying water for ophthalmic and injectable preparations. *Pharm J* 1989; 242: 169-171.
6. Smith VC. Pure water. *Mfg Chem* 1990; 61(3): 22-24.
7. Burrows WD, Nelson JH. IV fluidmakers: preparation of sterile water for injection in a field setting. *J Parenter Sci Technol* 1993; 47(3): 124-129.
8. Walker A. Drinking water - doubts about quality. *Br Med J* 1992; 304: 175-178.
9. World Health Organization. *Guidelines for Drinking-water Quality*, volume 1: recommendations. Geneva: World Health Organization, 1984.
10. Statutory Instrument 1147. The water supply (water quality) regulations 1989. London: HMSO, 1989.
11. Analysis of pharmaceutical water: meeting summary. *Pharm J* 1996; 257: 820-821.
12. Riedewald F. Biofilms in pharmaceutical waters. *Pharm Eng* 1997; Nov/Dec: 8-18.
13. FDA. Guide to inspections of high purity water systems, 1993.
14. McWilliam AJ. High purity water distribution systems. *Pharm Eng* 1995; Sept/Oct: 54-71.

21. General References

- Rössler R. Water and air, two important media in the manufacture of sterile pharmaceuticals, with regard to the GMP. *Drugs Made Ger* 1976; 19: 130-136.

22. Authors

A Ellison, RA Nash, MJ Wilkin.